SCORE Search Results Details for Application 10734564 and Search Result 20070524_133451_us-10-734-564-2.rag.

Score Home Page | Retrieve Application List | SCORE System Overview | SCORE FAQ | Comments / Suggestions

This page gives you Search Results detail for the Application 10734564 and Search Result 20070524_133451_us-10-734-564-2.rag.

Go Back to previous page

GenCore version 6.2.1

OM protein - protein search, using sw model

Run on: May 24, 2007, 16:25:44 ; Search time 132 Seconds
(without alignments)
615.374 Million cell updates/sec

Title: US-10-734-564-2
Perfect score: 903
Sequence: 1 MAQTNSFFMLISSLMFLSLS.....QKWKDVPCEDKFSFVCKFKN 166

Scoring table: BLOSUM62
Gapop 10.0 , Gapext 0.5

Searched: 2782304 seqs, 489333398 residues

Total number of hits satisfying chosen parameters: 2782304

Minimum DB seq length: 0
Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%
Maximum Match 100%
Listing first 45 summaries

Database : A_Geneseq_200701:*
1: geneseqp1980s:*
2: geneseqp1990s:*
3: geneseqp2000s:*
4: geneseqp2001s:*
5: geneseqp2002s:*
6: geneseqp2003as:*
7: geneseqp2003bs:*
8: geneseqp2004s:*
9: geneseqp2005s:*
10: geneseqp2006s:*
11: geneseqp2007s:*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	% Query Match	Length	DB	ID	Description
1	903	100.0	166	8	ADQ29576	Adq29576 Human Reg
2	890	98.6	166	8	ADU20784	Adu20784 Human Reg
3	884	97.9	166	2	AAR59288	Aar59288 Human reg
4	884	97.9	166	4	AAB71653	Aab71653 Human col
5	884	97.9	166	4	AAB71666	Aab71666 Human col
6	884	97.9	166	8	ADQ29578	Adq29578 Human Reg
7	884	97.9	166	8	ADQ60160	Adq60160 Human reg
8	884	97.9	166	8	ADS97994	Ads97994 Protein f
9	884	97.9	166	9	AEA04450	Aea04450 Human pro
10	884	97.9	174	3	AAB43737	Aab43737 Human can
11	874	96.8	166	1	AAP81514	Aap81514 Sequence
12	873	96.7	165	1	AAP94614	Aap94614 Human reg
13	810	89.7	146	2	AAR66591	Aar66591 Human reg
14	810	89.7	147	2	AAR06425	Aar06425 Reg prote
15	804	89.0	166	7	ADC78801	Adc78801 Human PRO
16	804	89.0	166	8	ADU20785	Adu20785 Human Reg
17	804	89.0	166	9	AEA04451	Aea04451 Human pro
18	804	89.0	166	10	AEF69882	Aef69882 Microsate
19	804	89.0	174	3	AAB54301	Aab54301 Human pan
20	799	88.5	144	2	AAR66592	Aar66592 Human reg
21	797	88.3	166	5	ABP69448	Abp69448 Human pol
22	797	88.3	166	8	ADS98793	Ads98793 Protein f
23	745	82.5	133	2	AAR66593	Aar66593 Human reg
24	669	74.1	165	2	AAR34535	Aar34535 MUREG-1.
25	626	69.3	165	1	AAP94615	Aap94615 Rat reg p
26	624	69.1	165	1	AAP81513	Aap81513 Sequence
27	624	69.1	165	1	AAP83188	Aap83188 Sequence
28	624	69.1	165	2	AAR59289	Aar59289 Rat reg p
29	609.5	67.5	173	2	AAR34536	Aar34536 MUREG-2.
30	582	64.5	146	2	AAR66594	Aar66594 Rat reg p
31	571	63.2	144	2	AAR66595	Aar66595 Rat reg p
32	564.5	62.5	294	4	ABG01855	Abg01855 Novel hum
33	564.5	62.5	294	8	ADS98699	Ads98699 Protein f
34	564.5	62.5	406	4	ABG03060	Abg03060 Novel hum
35	564.5	62.5	406	8	ADS98701	Ads98701 Protein f
36	564.5	62.5	558	4	ABG00465	Abg00465 Novel hum
37	536	59.4	132	8	ADO21124	Ado21124 Human car
38	534	59.1	133	2	AAR66596	Aar66596 Rat reg p
39	489	54.2	240	4	ABG20353	Abg20353 Novel hum
40	465	51.5	117	6	ABR57096	Abr57096 MLHR comp
41	423.5	46.9	175	5	ABJ10605	Abj10605 Human nov
42	423.5	46.9	175	8	ADO09871	Ado09871 Human NOV
43	418.5	46.3	175	2	AAR57117	Aar57117 Human Pan
44	418.5	46.3	175	2	AAR54098	Aar54098 Mouse PAP
45	418.5	46.3	175	7	ADC78805	Adc78805 Human PRO

ALIGNMENTS

RESULT 1
ADQ29576
ID ADQ29576 standard; protein; 166 AA.
XX
AC ADQ29576;

```
XX
DT   07-OCT-2004  (first entry)
XX
DE   Human Regl-alpha protein #1.
XX
KW   human; colon cancer; TIMP1; Regl-alpha;
KW   colorectal cancer-associated marker.
XX
OS   Homo sapiens.
XX
PN   EP1439393-A2.
XX
PD   21-JUL-2004.
XX
PF   15-DEC-2003; 2003EP-00257868.
XX
PR   13-DEC-2002; 2002US-0433554P.
PR   31-JUL-2003; 2003US-0491397P.
XX
PA   (FARB ) BAYER HEALTHCARE LLC.
PA   (MAYO-) MAYO FOUND MEDICAL EDUCATION & RES.
XX
PI   Astle JH,  Boardman LA,  Bugart LJ,  Burgess CC,  Catino TJ;
PI   Dwivedi P,  Huntress M,  Johnson KA,  Lewis ME,  Maimonis PJ,  Myerow SH;
PI   Brown-Shimer SLA,  Thiagalingam A,  Thibodeau SN,  Molino GA;
XX
DR   WPI; 2004-545561/53.
DR   N-PSDB; ADQ29575.
XX
PT   Diagnosing colon cancer in individual, preferably human, by detecting
PT   presence of TIMP 1 in sample, where presence of TIMP 1 in sample is
PT   indicative of colon cancer in individual.
XX
PS   Claim 7; SEQ ID NO 2; 433pp; English.
XX
CC   The invention comprises a method for diagnosing colon cancer in an
CC   individual, the method involves obtaining a serum sample from the
CC   individual and detecting the presence of either TIMP1 or Regl-alpha and
CC   an additional colorectal cancer-associated marker. The method of the
CC   invention is useful for diagnosing colon cancer in an individual. The
CC   present amino acid sequence represents a human Regl-alpha protein of the
CC   invention.
XX
SQ   Sequence 166 AA;

  Query Match             100.0%;  Score 903;  DB 8;  Length 166;
  Best Local Similarity   100.0%;  Pred. No. 7.2e-80;
  Matches  166;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 MAQTNSFFMLISSLMFLSLSQGQEAQTELPQARISCPEGTNAYRSYCYYFNEDRETWVDA 60
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db          1 MAQTNSFFMLISSLMFLSLSQGQEAQTELPQARISCPEGTNAYRSYCYYFNEDRETWVDA 60

Qy         61 DLYCQNMNSGNLVSVLTQAEGAFVASLIKESGTDDFNVWIGLHDPKKNRRWHWSSGSLVS 120
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db         61 DLYCQNMNSGNLVSVLTQAEGAFVASLIKESGTDDFNVWIGLHDPKKNRRWHWSSGSLVS 120

Qy        121 YKSWGIGAPSSVNPGYCVSLTSSTGFQKWKDVPCEDKFSFVCKFKN 166
              ||||||||||||||||||||||||||||||||||||||||||||||
Db        121 YKSWGIGAPSSVNPGYCVSLTSSTGFQKWKDVPCEDKFSFVCKFKN 166
```



```
RESULT 2
ADU20784
ID   ADU20784 standard; protein; 166 AA.
XX
AC   ADU20784;
XX
DT   13-JAN-2005  (first entry)
XX
DE   Human Reglalpha polypeptide, SEQ ID 1.
XX
KW   Reglalpha; Reglbeta; RegIII; RegIV; EXTL3; tumour; Reg signaling;
KW   pro-apoptosis; human.
XX
OS   Homo sapiens.
XX
PN   WO2004092352-A2.
XX
PD   28-OCT-2004.
XX
PF   14-APR-2004; 2004WO-US009286.
XX
PR   14-APR-2003; 2003US-0462317P.
PR   08-APR-2004; 2004US-00819991.
XX
PA   (UNIW ) UNIV WASHINGTON.
XX
PI   Dieckgraefe BK,  Korzenik JR;
XX
DR   WPI; 2004-766858/75.
XX
PT   New methods comprising delivering to a tumor cell an antisense construct
PT   comprising at least 15 nucleotides of the complement of a rat, mouse or
PT   human Reg gene family cDNA, useful for disrupting Reg signaling pathway.
XX
PS   Disclosure; Fig 2; 75pp; English.
XX
CC   The invention relates to a method that involves delivering to a tumour
CC   cell an antisense construct comprising at least 15 nucleotides of the
CC   complement of a rat, mouse or human Reg gene family cDNA selected from
CC   Reglalpha, Reglbeta, RegIII, RegIV, and EXTL3, where the tumour cell
CC   expresses an mRNA molecule that is complementary to native mRNA of the
CC   Reg gene. A COX-2 inhibitor, a chemotherapeutic drug and radiation is
CC   also administered to the tumour cell. This method also comprises
CC   administering to a tumour cell an RNA interference construct comprising
CC   at least 19 nucleotides of a rat, mouse, or human Reg gene family cDNA.
CC   The RNA interference construct encodes a small hairpin RNA. The RNA
CC   interference construct encodes each strand of an interference RNA duplex
CC   under the control of a separate promoter. The RNA interference construct
CC   contains an inverted repeat of the Reg family gene cDNA. The method
CC   alternatively comprises delivering to a tumour cell siRNA comprising 19-
CC   21 bp duplexes of a rat, mouse or human Reg gene family RNA, where the
CC   siRNA comprises 2 nt 3' overhangs, where the Reg gene mRNA produced by
CC   the tumour cell is cleaved. The method can comprise contacting a rat,
CC   mouse or human EXTL3 protein and a rat, mouse, or human Reg protein, in
CC   the presence or absence of a test substance; determining binding of the
CC   Reg protein to the EXTL3 protein in the presence and in the absence of a
CC   test compound; and identifying a test substance, which inhibits binding
CC   of the Reg protein to the EXTL3 protein. The method can also comprise
CC   delivering an inhibitor of binding of, or an antibody that binds to a
CC   rat, mouse, or human EXTL3 protein to a rat, mouse, or human Reg protein.
```

```
CC   The methods are useful for disrupting Reg signaling pathway to permit
CC   spontaneous and therapeutic induction of pro-apoptotic signals to be more
CC   effective. The present sequence represents a human RegIalpha polypeptide.
XX
SQ   Sequence 166 AA;

  Query Match             98.6%;  Score 890;  DB 8;  Length 166;
  Best Local Similarity   98.8%;  Pred. No. 1.3e-78;
  Matches  164;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy          1 MAQTNSFFMLISSLMFLSLSQGQEAQTELPQARISCPEGTNAYRSYCYYFNEDRETWVDA 60
              ||||||||||||||||||||||||||||||||||||||||||||||||||| ||||||||||
Db          1 MAQTNSFFMLISSLMFLSLSQGQEAQTELPQARISCPEGTNAYRSYCYVFNEDRETWVDA 60

Qy         61 DLYCQNMNSGNLVSVLTQAEGAFVASLIKESGTDDFNVWIGLHDPKKNRRWHWSSGSLVS 120
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db         61 DLYCQNMNSGNLVSVLTQAEGAFVASLIKESGTDDFNVWIGLHDPKKNRRWHWSSGSLVS 120

Qy        121 YKSWGIGAPSSVNPGYCVSLTSSTGFQKWKDVPCEDKFSFVCKFKN 166
              ||||| |||||||||||||||||||||||||||||||||||||||||
Db        121 YKSWGTGAPSSVNPGYCVSLTSSTGFQKWKDVPCEDKFSFVCKFKN 166


RESULT 3
AAR59288
ID   AAR59288 standard; protein; 166 AA.
XX
AC   AAR59288;
XX
DT   25-MAR-2003  (revised)
DT   03-FEB-1995  (first entry)
XX
DE   Human reg protein.
XX
KW   Human reg protein; blood sugar level depressant; hypoglycaemic agent;
KW   diabetes; hyperglycaemia; cell proliferation; islets of Langerhans.
XX
OS   Homo sapiens.
XX
FH   Key             Location/Qualifiers
FT   Peptide         21. .166
FT                   /note= "claimed subfragment"
FT   Peptide         23. .166
FT                   /note= "claimed subfragment"
FT   Peptide         34. .166
FT                   /note= "claimed subfragment"
XX
PN   WO9412203-A1.
XX
PD   09-JUN-1994.
XX
PF   01-DEC-1993;   93WO-JP001746.
XX
PR   01-DEC-1992;   92JP-00322121.
PR   19-APR-1993;   93JP-00091576.
XX
PA   (SHIO ) SHIONOGI SEIYAKU KK.
XX
PI   Okamoto H;
XX
DR   WPI; 1994-199962/24.
```



```
XX
PT   Sugar level depressants and cell proliferation agents comprising reg
PT   proteins - for treatment of diabetes, and inducing growth of islets of
PT   Langerhans.
XX
PS   Claim 1; Page 11; 20pp; Japanese.
XX
CC   Three specified subfragments of the human reg protein are claimed for use
CC   as blood sugar level depressants to treat diabetes. They are also useful
CC   to induce proliferation of cells in the islets of Langerhans. (Updated on
CC   25-MAR-2003 to correct PN field.)
XX
SQ   Sequence 166 AA;

  Query Match             97.9%;  Score 884;  DB 2;  Length 166;
  Best Local Similarity   97.6%;  Pred. No. 5.2e-78;
  Matches  162;  Conservative    2;  Mismatches    2;  Indels    0;  Gaps    0;

Qy          1 MAQTNSFFMLISSLMFLSLSQGQEAQTELPQARISCPEGTNAYRSYCYYFNEDRETWVDA 60
              ||||:|:||||| ||||| ||||||||||||||||||||||||||||||||||||||||||
Db          1 MAQTSSYFMLISCLMFLSQSQGQEAQTELPQARISCPEGTNAYRSYCYYFNEDRETWVDA 60

Qy         61 DLYCQNMNSGNLVSVLTQAEGAFVASLIKESGTDDFNVWIGLHDPKKNRRWHWSSGSLVS 120
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db         61 DLYCQNMNSGNLVSVLTQAEGAFVASLIKESGTDDFNVWIGLHDPKKNRRWHWSSGSLVS 120

Qy        121 YKSWGIGAPSSVNPGYCVSLTSSTGFQKWKDVPCEDKFSFVCKFKN 166
              ||||||||||||||||||||||||||||||||||||||||||||||||
Db        121 YKSWGIGAPSSVNPGYCVSLTSSTGFQKWKDVPCEDKFSFVCKFKN 166


RESULT 4
AAB71653
ID   AAB71653 standard; protein; 166 AA.
XX
AC   AAB71653;
XX
DT   10-MAY-2001  (first entry)
XX
DE   Human colon associated protein #1.
XX
KW   Human; colon; cancer; disease.
XX
OS   Homo sapiens.
XX
PN   WO200112781-A1.
XX
PD   22-FEB-2001.
XX
PF   11-AUG-2000; 2000WO-US022157.
XX
PR   13-AUG-1999;   99US-0148680P.
XX
PA   (HUMA-) HUMAN GENOME SCI INC.
XX
PI   Birse CE,  Rosen CA;
XX
DR   WPI; 2001-147551/15.
XX
PT   Nucleic acids encoding 13 human colon cancer associated polypeptides,
PT   useful for preventing, diagnosing and/or treating e.g. cancers
```

```
PT   (especially colon cancer), Parkinson's disease and diabetic retinopathy.
XX
PS   Claim 11; Page 315-316; 326pp; English.
XX
CC   The present invention relates to 13 human colon cancer-associated
CC   proteins. These proteins and the nucleic acid encoding them may be used
CC   in the prevention, diagnosis and treatment of diseases associated with
CC   inappropriate colon cancer-associated protein expression
XX
SQ   Sequence 166 AA;

  Query Match             97.9%;  Score 884;  DB 4;  Length 166;
  Best Local Similarity   97.6%;  Pred. No. 5.2e-78;
  Matches  162;  Conservative    2;  Mismatches    2;  Indels    0;  Gaps    0;

Qy          1 MAQTNSFFMLISSLMFLSLSQGQEAQTELPQARISCPEGTNAYRSYCYYFNEDRETWVDA 60
              ||||:|:||||| ||||| ||||||||||||||||||||||||||||||||||||||||
Db          1 MAQTSSYFMLISCLMFLSQSQGQEAQTELPQARISCPEGTNAYRSYCYYFNEDRETWVDA 60

Qy         61 DLYCQNMNSGNLVSVLTQAEGAFVASLIKESGTDDFNVWIGLHDPKKNRRWHWSSGSLVS 120
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db         61 DLYCQNMNSGNLVSVLTQAEGAFVASLIKESGTDDFNVWIGLHDPKKNRRWHWSSGSLVS 120

Qy        121 YKSWGIGAPSSVNPGYCVSLTSSTGFQKWKDVPCEDKFSFVCKFKN 166
              ||||||||||||||||||||||||||||||||||||||||||||||
Db        121 YKSWGIGAPSSVNPGYCVSLTSSTGFQKWKDVPCEDKFSFVCKFKN 166


RESULT 5
AAB71666
ID   AAB71666 standard; protein; 166 AA.
XX
AC   AAB71666;
XX
DT   10-MAY-2001  (first entry)
XX
DE   Human colon associated protein #14.
XX
KW   Human; colon; cancer; disease.
XX
OS   Homo sapiens.
XX
PN   WO200112781-A1.
XX
PD   22-FEB-2001.
XX
PF   11-AUG-2000; 2000WO-US022157.
XX
PR   13-AUG-1999;   99US-0148680P.
XX
PA   (HUMA-) HUMAN GENOME SCI INC.
XX
PI   Birse CE,  Rosen CA;
XX
DR   WPI; 2001-147551/15.
XX
PT   Nucleic acids encoding 13 human colon cancer associated polypeptides,
PT   useful for preventing, diagnosing and/or treating e.g. cancers
PT   (especially colon cancer), Parkinson's disease and diabetic retinopathy.
XX
PS   Claim 11; Page 322-323; 326pp; English.
```



```
XX
CC   The present invention relates to 13 human colon cancer-associated
CC   proteins. These proteins and the nucleic acid encoding them may be used
CC   in the prevention, diagnosis and treatment of diseases associated with
CC   inappropriate colon cancer-associated protein expression
XX
SQ   Sequence 166 AA;

  Query Match             97.9%;  Score 884;  DB 4;  Length 166;
  Best Local Similarity   97.6%;  Pred. No. 5.2e-78;
  Matches  162;  Conservative    2;  Mismatches    2;  Indels    0;  Gaps    0;

Qy          1 MAQTNSFFMLISSLMFLSLSQGQEAQTELPQARISCPEGTNAYRSYCYYFNEDRETWVDA 60
              ||||:|:||||| ||||| ||||||||||||||||||||||||||||||||||||||||
Db          1 MAQTSSYFMLISCLMFLSQSQGQEAQTELPQARISCPEGTNAYRSYCYYFNEDRETWVDA 60

Qy         61 DLYCQNMNSGNLVSVLTQAEGAFVASLIKESGTDDFNVWIGLHDPKKNRRWHWSSGSLVS 120
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db         61 DLYCQNMNSGNLVSVLTQAEGAFVASLIKESGTDDFNVWIGLHDPKKNRRWHWSSGSLVS 120

Qy        121 YKSWGIGAPSSVNPGYCVSLTSSTGFQKWKDVPCEDKFSFVCKFKN 166
              ||||||||||||||||||||||||||||||||||||||||||||||
Db        121 YKSWGIGAPSSVNPGYCVSLTSSTGFQKWKDVPCEDKFSFVCKFKN 166


RESULT 6
ADQ29578
ID   ADQ29578 standard; protein; 166 AA.
XX
AC   ADQ29578;
XX
DT   07-OCT-2004  (first entry)
XX
DE   Human Reg1-alpha protein #2.
XX
KW   human; colon cancer; TIMP1; Reg1-alpha;
KW   colorectal cancer-associated marker.
XX
OS   Homo sapiens.
XX
PN   EP1439393-A2.
XX
PD   21-JUL-2004.
XX
PF   15-DEC-2003; 2003EP-00257868.
XX
PR   13-DEC-2002; 2002US-0433554P.
PR   31-JUL-2003; 2003US-0491397P.
XX
PA   (FARB ) BAYER HEALTHCARE LLC.
PA   (MAYO-) MAYO FOUND MEDICAL EDUCATION & RES.
XX
PI   Astle JH,  Boardman LA,  Bugart LJ,  Burgess CC,  Catino TJ;
PI   Dwivedi P,  Huntress M,  Johnson KA,  Lewis ME,  Maimonis PJ,  Myerow SH;
PI   Brown-Shimer SLA,  Thiagalingam A,  Thibodeau SN,  Molino GA;
XX
DR   WPI; 2004-545561/53.
DR   N-PSDB; ADQ29577.
XX
PT   Diagnosing colon cancer in individual, preferably human, by detecting
PT   presence of TIMP 1 in sample, where presence of TIMP 1 in sample is
```

```
PT   indicative of colon cancer in individual.
XX
PS   Claim 7; SEQ ID NO 4; 433pp; English.
XX
CC   The invention comprises a method for diagnosing colon cancer in an
CC   individual, the method involves obtaining a serum sample from the
CC   individual and detecting the presence of either TIMP1 or Reg1-alpha and
CC   an additional colorectal cancer-associated marker. The method of the
CC   invention is useful for diagnosing colon cancer in an individual. The
CC   present amino acid sequence represents a human Reg1-alpha protein of the
CC   invention.
XX
SQ   Sequence 166 AA;

  Query Match             97.9%;  Score 884;  DB 8;  Length 166;
  Best Local Similarity   97.6%;  Pred. No. 5.2e-78;
  Matches  162;  Conservative    2;  Mismatches    2;  Indels    0;  Gaps    0;

Qy          1 MAQTNSFFMLISSLMFLSLSQGQEAQTELPQARISCPEGTNAYRSYCYYFNEDRETWVDA 60
              ||||:|:||||| ||||| ||||||||||||||||||||||||||||||||||||||||
Db          1 MAQTSSYFMLISCLMFLSQSQGQEAQTELPQARISCPEGTNAYRSYCYYFNEDRETWVDA 60

Qy         61 DLYCQNMNSGNLVSVLTQAEGAFVASLIKESGTDDFNVWIGLHDPKKNRRWHWSSGSLVS 120
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db         61 DLYCQNMNSGNLVSVLTQAEGAFVASLIKESGTDDFNVWIGLHDPKKNRRWHWSSGSLVS 120

Qy        121 YKSWGIGAPSSVNPGYCVSLTSSTGFQKWKDVPCEDKFSFVCKFKN 166
              ||||||||||||||||||||||||||||||||||||||||||||||
Db        121 YKSWGIGAPSSVNPGYCVSLTSSTGFQKWKDVPCEDKFSFVCKFKN 166


RESULT 7
ADQ60160
ID   ADQ60160 standard; protein; 166 AA.
XX
AC   ADQ60160;
XX
DT   07-OCT-2004  (first entry)
XX
DE   Human regenerating islet-derived 1 alpha (REG Ialpha) protein.
XX
KW   inflammatory bowel disease; IBD; antiinflammatory; antiulcer;
KW   gastrointestinal; ulcerative colitis; Crohn's disease; human;
KW   regenerating islet-derived 1 alpha; REG Ialpha; receptor.
XX
OS   Homo sapiens.
XX
PN   JP2004194534-A.
XX
PD   15-JUL-2004.
XX
PF   17-DEC-2002; 2002JP-00365079.
XX
PR   17-DEC-2002; 2002JP-00365079.
XX
PA   (SUMU ) SUMITOMO SEIYAKU KK.
XX
DR   WPI; 2004-537122/52.
DR   N-PSDB; ADQ60157.
XX
PT   New markers of inflammatory bowel disease comprise at least 15 base pairs
```



```
PT   of the glucose-dependent insulinotropic polypeptide receptor, granulocyte
PT   colony-stimulating factor receptor, or regenerating islet-derived 1 alpha
PT   genes.
XX
PS   Example 3; SEQ ID NO 6; 57pp; Japanese.
XX
CC   The invention relates to a novel marker of inflammatory bowel disease
CC   (IBD) which comprises a polynucleotide having at least 15 contiguous
CC   bases of the base sequence of the glucose-dependent insulinotropic
CC   polypeptide receptor (GIPR) gene, granulocyte colony-stimulating factor
CC   receptor (GCSFR) gene or regenerating islet-derived 1 alpha (REG Ialpha)
CC   gene. The marker of the invention demonstrates antiinflammatory,
CC   antiulcer and gastrointestinal activities and may be useful as a probe or
CC   primer in the detection and subsequent treatment of inflammatory bowel
CC   disease and other conditions such as ulcerative colitis and Crohn's
CC   disease. The current sequence is that of the human regenerating islet-
CC   derived 1 alpha (REG Ialpha) protein of the invention.
XX
SQ   Sequence 166 AA;

  Query Match             97.9%;  Score 884;  DB 8;  Length 166;
  Best Local Similarity   97.6%;  Pred. No. 5.2e-78;
  Matches  162;  Conservative    2;  Mismatches    2;  Indels    0;  Gaps    0;

Qy          1 MAQTNSFFMLISSLMFLSLSQGQEAQTELPQARISCPEGTNAYRSYCYYFNEDRETWVDA 60
              ||||:|:||||| ||||| ||||||||||||||||||||||||||||||||||||||||
Db          1 MAQTSSYFMLISCLMFLSQSQGQEAQTELPQARISCPEGTNAYRSYCYYFNEDRETWVDA 60

Qy         61 DLYCQNMNSGNLVSVLTQAEGAFVASLIKESGTDDFNVWIGLHDPKKNRRWHWSSGSLVS 120
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db         61 DLYCQNMNSGNLVSVLTQAEGAFVASLIKESGTDDFNVWIGLHDPKKNRRWHWSSGSLVS 120

Qy        121 YKSWGIGAPSSVNPGYCVSLTSSTGFQKWKDVPCEDKFSFVCKFKN 166
              ||||||||||||||||||||||||||||||||||||||||||||||
Db        121 YKSWGIGAPSSVNPGYCVSLTSSTGFQKWKDVPCEDKFSFVCKFKN 166


RESULT 8
ADS97994
ID   ADS97994 standard; protein; 166 AA.
XX
AC   ADS97994;
XX
DT   30-DEC-2004  (first entry)
XX
DE   Protein factor discovery related isolated human polypeptide, SEQ ID 258.
XX
KW   antiinflammatory; cytostatic; antimicrobial; gene therapy; inflammation;
KW   leukaemia; nervous system disorder; infection.
XX
OS   Homo sapiens.
XX
PN   WO2004087874-A2.
XX
PD   14-OCT-2004.
XX
PF   24-MAR-2004; 2004WO-US009202.
XX
PR   28-MAR-2003; 2003US-0458824P.
XX
PA   (NUVE-) NUVELO INC.
```

```
PA   (DRMA/) DRMANAC R T.
XX
PI   Tang YT,  Zhou P,  Wang J,  Wang ZW,  Hu T;
XX
DR   WPI; 2004-737686/72.
DR   N-PSDB; ADS97759.
XX
PT   New polynucleotides encoding a polypeptide with biological activity,
PT   useful for treating inflammation, leukemias, nervous system disorders, or
PT   infections.
XX
PS   Claim 20; SEQ ID NO 258; 253pp; English.
XX
CC   The invention relates to a novel isolated polynucleotide comprising any
CC   of the 235 nucleotide sequences described in the specification. The
CC   invention further comprises: an isolated polynucleotide encoding a
CC   polypeptide with biological activity, where the polynucleotide hybridizes
CC   to one of the 235 novel polynucleotides under stringent hybridization
CC   conditions, or having greater than about 99% sequence identity with the
CC   novel polynucleotide; a vector comprising a novel polynucleotide; an
CC   expression vector comprising the novel polynucleotide; a host cell
CC   genetically engineered to comprise the novel polynucleotide, which can be
CC   operatively associated with a regulatory sequence that modulates
CC   expression of the polynucleotide in the host cell; an isolated
CC   polypeptide encoded by the novel polynucleotide, or a polynucleotide
CC   hybridizing under stringent conditions to the novel polynucleotide; a
CC   composition comprising the polypeptide and a carrier; an antibody
CC   directed against the polypeptide; a method for detecting the novel
CC   polynucleotide in a sample; a method for detecting the polypeptide in a
CC   sample; a method for identifying a compound that binds to the polypeptide
CC   ; a method for producing the polypeptide; an isolated polypeptide
CC   comprising any of the 235 amino acid sequences described in the
CC   specification; and a collection of polynucleotides comprising of at least
CC   one of the polynucleotides cited above. The polypeptides and
CC   polynucleotides of the invention have antiinflammatory, cytostatic, and
CC   antimicrobial activities. The novel polynucleotide may be used to treat
CC   disorders by gene therapy. The polypeptides and polynucleotides are
CC   useful for treating inflammation, leukaemias, nervous system disorders,
CC   or infections. This sequence represents one of the 235 novel isolated
CC   polypeptides of the invention.
XX
SQ   Sequence 166 AA;

  Query Match             97.9%;  Score 884;  DB 8;  Length 166;
  Best Local Similarity   97.6%;  Pred. No. 5.2e-78;
  Matches  162;  Conservative    2;  Mismatches    2;  Indels    0;  Gaps    0;

Qy          1 MAQTNSFFMLISSLMFLSLSQGQEAQTELPQARISCPEGTNAYRSYCYYFNEDRETWVDA 60
              ||||:|:||||| ||||| ||||||||||||||||||||||||||||||||||||||||||
Db          1 MAQTSSYFMLISCLMFLSQSQGQEAQTELPQARISCPEGTNAYRSYCYYFNEDRETWVDA 60

Qy         61 DLYCQNMNSGNLVSVLTQAEGAFVASLIKESGTDDFNVWIGLHDPKKNRRWHWSSGSLVS 120
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db         61 DLYCQNMNSGNLVSVLTQAEGAFVASLIKESGTDDFNVWIGLHDPKKNRRWHWSSGSLVS 120

Qy        121 YKSWGIGAPSSVNPGYCVSLTSSTGFQKWKDVPCEDKFSFVCKFKN 166
              ||||||||||||||||||||||||||||||||||||||||||||||
Db        121 YKSWGIGAPSSVNPGYCVSLTSSTGFQKWKDVPCEDKFSFVCKFKN 166


RESULT 9
```



```
AEA04450
ID   AEA04450 standard; protein; 166 AA.
XX
AC   AEA04450;
XX
DT   28-JUL-2005  (first entry)
XX
DE   Human protein from gene overexpressed in cancer, REG1A.
XX
KW   Tumor marker; colon tumor; cancer; cytostatic; neoplasm; diagnostic;
KW   microarray; drug screening.
XX
OS   Homo sapiens.
XX
PN   WO2005044990-A2.
XX
PD   19-MAY-2005.
XX
PF   01-NOV-2004; 2004WO-US036404.
XX
PR   04-NOV-2003; 2003US-00700439.
XX
PA   (FARB ) BAYER HEALTHCARE LLC.
PA   (MAYO-) MAYO FOUND MEDICAL EDUCATION & RES.
XX
PI   Burgess C,  Myerow S,  Thiagalingam A,  Maimonis P,  Molino G;
PI   Burgart L,  Boardman LA,  Thibodeau S,  Lewis M;
XX
DR   WPI; 2005-372198/38.
DR   N-PSDB; AEA04357.
DR   REFSEQ; NP_002900.
XX
PT   Detecting expression of one or more nucleic acid sequences in biological
PT   sample, useful for detecting cancer, comprises detecting a change in the
PT   expression level of one or more nucleic acid sequences relative to a
PT   control expression level.
XX
PS   Claim 20; SEQ ID NO 95; 256pp; English.
XX
CC   The invention relates to detecting differential expression of one or more
CC   nucleic acid sequences (appearing as AEA04356-AEA04448 in a biological
CC   sample comprising obtaining the sample from a subject, and detecting a
CC   change in the expression level of one or more nucleic acid sequences
CC   relative to a control expression level of the nucleic acid sequences, is
CC   new. Also included are detecting cancer (or a pre-malignant condition
CC   thereof) in a subject (comprising comparing the expression level of one
CC   or more nucleic acid sequences in a biological sample from the subject
CC   with a control expression level of the nucleic acid sequences, where a
CC   change of at least two-fold in the expression level of the nucleic acid
CC   sequences is indicative of cancer or pre-malignant condition), monitoring
CC   the onset (or progression, or regression) of cancer (or a pre-malignant
CC   condition) in a subject (by detecting in a biological sample of the
CC   subject at a first point in time the expression of one or more nucleic
CC   acid sequences, repeating the first step at a subsequent point in time
CC   and comparing the expression level detected, where a change in the
CC   expression level is indicative of progression of cancer or its pre-
CC   malignant condition in the subject), determining prognosis for cancer or
CC   its pre-malignant condition in a subject (comprising detecting in a
CC   biological sample of the subject, the expression level of one or more
CC   nucleic acid sequences, comparing the expression level with a reference
CC   expression level of the nucleic acid sequences and evaluating the
```

```
CC   prognosis of the subject based on the comparison), determining the
CC   efficacy of a test compound for inhibiting cancer in a subject,
CC   determining the efficacy of a therapy for inhibiting cancer in a subject,
CC   selecting a composition for inhibiting cancer in a subject, inhibiting
CC   cancer in a subject, a polypeptide encoded by the nucleic acids above
CC   (appearing as AEA04449-AEA04541), an antibody that specifically binds to
CC   the polypeptide sequence, and detecting in a biological sample the
CC   presence of a polypeptide. The method is useful for detecting
CC   differential expression of one or more nucleic acid sequences in a
CC   biological sample, which is useful for detecting cancer (especially colon
CC   cancer), monitoring the onset, progression, or regression of cancer or a
CC   pre-malignant condition, or determining prognosis for cancer or its pre-
CC   malignant condition in a subject, or for determining the efficacy of a
CC   test compound for inhibiting cancer in a subject. The compound is useful
CC   for inhibiting cancer in a subject. The antibodies may also be used to
CC   treat cancer. The present sequence is a protein from a human gene over-
CC   expressed in cancer samples.
XX
SQ   Sequence 166 AA;

  Query Match             97.9%;  Score 884;  DB 9;  Length 166;
  Best Local Similarity   97.6%;  Pred. No. 5.2e-78;
  Matches  162;  Conservative    2;  Mismatches    2;  Indels    0;  Gaps    0;

Qy          1 MAQTNSFFMLISSLMFLSLSQGQEAQTELPQARISCPEGTNAYRSYCYYFNEDRETWVDA 60
              ||||:|:||||| ||||| ||||||||||||||||||||||||||||||||||||||||
Db          1 MAQTSSYFMLISCLMFLSQSQGQEAQTELPQARISCPEGTNAYRSYCYYFNEDRETWVDA 60

Qy         61 DLYCQNMNSGNLVSVLTQAEGAFVASLIKESGTDDFNVWIGLHDPKKNRRWHWSSGSLVS 120
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db         61 DLYCQNMNSGNLVSVLTQAEGAFVASLIKESGTDDFNVWIGLHDPKKNRRWHWSSGSLVS 120

Qy        121 YKSWGIGAPSSVNPGYCVSLTSSTGFQKWKDVPCEDKFSFVCKFKN 166
              ||||||||||||||||||||||||||||||||||||||||||||||||
Db        121 YKSWGIGAPSSVNPGYCVSLTSSTGFQKWKDVPCEDKFSFVCKFKN 166


RESULT 10
AAB43737
ID   AAB43737 standard; protein; 174 AA.
XX
AC   AAB43737;
XX
DT   08-FEB-2001  (first entry)
XX
DE   Human cancer associated protein sequence SEQ ID NO:1182.
XX
KW   Human; cancer associated gene; cancer antigen; detection; cancer;
KW   diagnosis; cytostatic; proliferative; vulnerary; immunomodulator;
KW   antidiabetic; antiasthmatic; antirheumatic; antiarthritic; antiviral;
KW   antiinflammatory; antithyroid; antiallergic; antibacterial; cardiant;
KW   dermatological; neuroprotective; thrombolytic; coagulant; nootropic;
KW   vasotropic; antipsoriatic; antiangiogenic; gene therapy; inflammation;
KW   immune disorder; haematopoietic cell disorder; autoimmune disorder;
KW   allergic reaction; graft versus host disease; organ rejection;
KW   haemostatic; thrombolytic; cardiovascular disorder; infection;
KW   neurological disease; drug screening.
XX
OS   Homo sapiens.
XX
PN   WO200055350-A1.
```



```
XX
PD   21-SEP-2000.
XX
PF   08-MAR-2000; 2000WO-US005882.
XX
PR   12-MAR-1999;   99US-0124270P.
XX
PA   (HUMA-) HUMAN GENOME SCI INC.
XX
PI   Rosen CA,  Ruben SM;
XX
DR   WPI; 2000-587533/55.
DR   N-PSDB; AAC77946.
XX
PT   Novel isolated nucleic acids comprising sequences encoding peptides
PT   useful for treating or diagnosing e.g. cancer.
XX
PS   Claim 11; Page 1805-1806; 2352pp; English.
XX
CC   AAC77607 to AAC78448 encode the human cancer associated proteins given in
CC   AAB43398 to AAB44239. The proteins can have activities based on the
CC   tissues and cells the genes are expressed in. Example of activities
CC   include: cytostatic; proliferative; vulnerary; immunomodulator;
CC   antidiabetic; antiasthmatic; antirheumatic; antiarthritic;
CC   antiinflammatory; antithyroid; antiallergic; antibacterial; antiviral;
CC   dermatological; neuroprotective; cardiant; thrombolytic; coagulant;
CC   nootropic; vasotropic; antipsoriatic and antiangiogenic. The
CC   polynucleotides and polypeptides can be used for preventing, treating or
CC   ameliorating medical conditions and diagnosing pathological conditions.
CC   Polynucleotides, polypeptides, antibodies, agonists and antagonists from
CC   the present invention may be used to treat immune disorders by activating
CC   or inhibiting the proliferation, differentiation or mobilisation of
CC   immune cells, to treat disorders of haematopoietic cells, autoimmune
CC   disorders, allergic reactions, graft versus host disease and organ
CC   rejection, modulate haemostatic or thrombolytic activity, modulate
CC   inflammation, cancers, cardiovascular disorders, neurological disease and
CC   bacterial or viral infections. The peptides, nucleotides, antibodies,
CC   agonists and antagonists may be also be used in drug screens. AAC78449 to
CC   AAC78457 and AAB44240 represent sequences used in the exemplification of
CC   the present invention
XX
SQ   Sequence 174 AA;

  Query Match             97.9%;  Score 884;  DB 3;  Length 174;
  Best Local Similarity   97.6%;  Pred. No. 5.5e-78;
  Matches  162;  Conservative    2;  Mismatches    2;  Indels    0;  Gaps    0;

Qy          1 MAQTNSFFMLISSLMFLSLSQGQEAQTELPQARISCPEGTNAYRSYCYYFNEDRETWVDA 60
              ||||:|:||||| ||||| ||||||||||||||||||||||||||||||||||||||||
Db          9 MAQTSSYFMLISCLMFLSQSQGQEAQTELPQARISCPEGTNAYRSYCYYFNEDRETWVDA 68

Qy         61 DLYCQNMNSGNLVSVLTQAEGAFVASLIKESGTDDFNVWIGLHDPKKNRRWHWSSGSLVS 120
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db         69 DLYCQNMNSGNLVSVLTQAEGAFVASLIKESGTDDFNVWIGLHDPKKNRRWHWSSGSLVS 128

Qy        121 YKSWGIGAPSSVNPGYCVSLTSSTGFQKWKDVPCEDKFSFVCKFKN 166
              ||||||||||||||||||||||||||||||||||||||||||||||||
Db        129 YKSWGIGAPSSVNPGYCVSLTSSTGFQKWKDVPCEDKFSFVCKFKN 174


RESULT 11
```

```
AAP81514
ID   AAP81514 standard; protein; 166 AA.
XX
AC   AAP81514;
XX
DT   25-MAR-2003  (revised)
DT   02-FEB-1991  (first entry)
XX
DE   Sequence encoded by human reg cDNA.
XX
KW   Pancreatic islet B cell regeneration; diabetes; therapy.
XX
OS   Homo sapiens.
XX
PN   EP286114-A.
XX
PD   12-OCT-1988.
XX
PF   08-APR-1988;   88EP-00105623.
XX
PR   09-APR-1987;   87JP-00087807.
PR   10-AUG-1987;   87JP-00200514.
PR   24-MAR-1988;   88JP-00071671.
PR   04-AUG-1988;   88JP-00195727.
PR   09-AUG-1988;   88EP-00112942.
XX
PA   (SHIO ) SHIONOGI SEIYAKU KK.
XX
PI   Okamoto H;
XX
DR   WPI; 1988-287314/41.
DR   N-PSDB; AAN81962.
XX
PT   Rat and human reg genes - used for producing proteins for regeneration of
PT   insulin-producing pancreatic B cells of patients with diabetes.
XX
PS   Disclosure; Fig 3; 12pp; English.
XX
CC   The reg gene is specifically expressed in regenerating pancreatic islet B
CC   cells. A gene hybridising to a probe corresponding to at least a part of
CC   the whole base sequence of rat reg gene or human reg gene is claimed. By
CC   mass producing the proteins encoded by the gene it may be possible to
CC   open a new dimension in the treatment of diabetes (Updated on 25-MAR-2003
CC   to correct PD field.) (Updated on 25-MAR-2003 to correct PR field.)
XX
SQ   Sequence 166 AA;

  Query Match            96.8%;  Score 874;  DB 1;  Length 166;
  Best Local Similarity  96.4%;  Pred. No. 4.9e-77;
  Matches  160;  Conservative    3;  Mismatches    3;  Indels    0;  Gaps    0;

Qy          1 MAQTNSFFMLISSLMFLSLSQGQEAQTELPQARISCPEGTNAYRSYCYYFNEDRETWVDA 60
              ||||:|:||||| ||||| ||||||||||||||||||||||||||||||||||||||||
Db          1 MAQTSSYFMLISCLMFLSQSQGQEAQTELPQARISCPEGTNAYRSYCYYFNEDRETWVDA 60

Qy         61 DLYCQNMNSGNLVSVLTQAEGAFVASLIKESGTDDFNVWIGLHDPKKNRRWHWSSGSLVS 120
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db         61 DLYCQNMNSGNLVSVLTQAEGAFVASLIKESGTDDFNVWIGLHDPKKNRRWHWSSGSLVS 120

Qy        121 YKSWGIGAPSSVNPGYCVSLTSSTGFQKWKDVPCEDKFSFVCKFKN 166
              |||||||||||||||||||||||| |||||||||:||||||||||
```



```
Db        121 YKSWGIGAPSSVNPGYCVSLTSSTGLQKWKDVPCEEKFSFVCKFKN 166


RESULT 12
AAP94614
ID   AAP94614 standard; protein; 165 AA.
XX
AC   AAP94614;
XX
DT   25-MAR-2003  (revised)
DT   21-JUN-1990  (first entry)
XX
DE   Human reg protein.
XX
KW   reg proteins; islet cells; diabetes; insulin; ds.
XX
OS   Homo sapiens.
XX
PN   EP303233-A.
XX
PD   15-FEB-1989.
XX
PF   09-AUG-1988;   88EP-00112942.
XX
PR   10-AUG-1987;   87JP-00200514.
XX
PA   (SHIO ) SHIONOGI & CO LTD.
XX
PI   Okamoto H,  Itoh T,  Teraoka H,  Tsuzuki H,  Yoshida M;
XX
DR   WPI; 1989-048048/07.
DR   N-PSDB; AAP94614.
XX
PT   New human reg proteins - useful for regenerating islet B cells in
PT   diabetes treatment.
XX
PS   Claim 1; Fig 1; 19pp; English.
XX
CC   Protein product for reg gene useful in regeneration of human pancreatic
CC   islet B cells in treatment of diabetes. Derivatives from bases 21(Gly),
CC   22(Gln), 23(Glu), 24(Ala), 25(Gln), 30(Gln), 31(Ala) and 33(Ile) to
CC   165(Asn) are also functional. (Updated on 25-MAR-2003 to correct PA
CC   field.) (Updated on 25-MAR-2003 to correct PI field.)
XX
SQ   Sequence 165 AA;

  Query Match            96.7%;  Score 873;  DB 1;  Length 165;
  Best Local Similarity  97.0%;  Pred. No. 6.1e-77;
  Matches  160;  Conservative    2;  Mismatches    3;  Indels    0;  Gaps    0;

Qy          2 AQTNSFFMLISSLMFLSLSQGQEAQTELPQARISCPEGTNAYRSYCYYFNEDRETWVDAD 61
              |||:|:||||| ||||| ||||||||||||||||||||||||||||||||||||||||||
Db          1 AQTSSYFMLISCLMFLSQSQGQEAQTELPQARISCPEGTNAYRSYCYYFNEDRETWVDAD 60

Qy         62 LYCQNMNSGNLVSVLTQAEGAFVASLIKESGTDDFNVWIGLHDPKKNRRWHWSSGSLVSY 121
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db         61 LYCQNMNSGNLVSVLTQAEGAFVASLIKESGTDDFNVWIGLHDPKKNRRWHWSSGSLVSY 120

Qy        122 KSWGIGAPSSVNPGYCVSLTSSTGFQKWKDVPCEDKFSFVCKFKN 166
              |||||||||||||||||||||||| ||||||||||||||||||||
Db        121 KSWGIGAPSSVNPGYCVSLTSSTGLQKWKDVPCEDKFSFVCKFKN 165
```

SCORE Search Results Details for Application 10734564 and Search Result 20070524_133451_us-10-734-564-4.rag.

Score Home Page | Retrieve Application List | SCORE System Overview | SCORE FAQ | Comments / Suggestions

This page gives you Search Results detail for the Application 10734564 and Search Result 20070524_133451_us-10-734-564-4.rag.

Go Back to previous page

GenCore version 6.2.1

OM protein - protein search, using sw model

Run on: May 24, 2007, 16:25:44 ; Search time 132 Seconds
(without alignments)
615.374 Million cell updates/sec

Title: US-10-734-564-4
Perfect score: 908
Sequence: 1 MAQTSSYFMLISCLMFLSQS.....QKWKDVPCEDKFSFVCKFKN 166

Scoring table: BLOSUM62
Gapop 10.0 , Gapext 0.5

Searched: 2782304 seqs, 489333398 residues

Total number of hits satisfying chosen parameters: 2782304

Minimum DB seq length: 0
Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%
Maximum Match 100%
Listing first 45 summaries

Database : A_Geneseq_200701:*
1: geneseqp1980s:*
2: geneseqp1990s:*
3: geneseqp2000s:*
4: geneseqp2001s:*
5: geneseqp2002s:*
6: geneseqp2003as:*
7: geneseqp2003bs:*
8: geneseqp2004s:*
9: geneseqp2005s:*
10: geneseqp2006s:*
11: geneseqp2007s:*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	% Query Match	Length	DB	ID	Description
1	908	100.0	166	2	AAR59288	Aar59288 Human reg
2	908	100.0	166	4	AAB71653	Aab71653 Human col
3	908	100.0	166	4	AAB71666	Aab71666 Human col
4	908	100.0	166	8	ADQ29578	Adq29578 Human Reg
5	908	100.0	166	8	ADQ60160	Adq60160 Human reg
6	908	100.0	166	8	ADS97994	Ads97994 Protein f
7	908	100.0	166	9	AEA04450	Aea04450 Human pro
8	908	100.0	174	3	AAB43737	Aab43737 Human can
9	898	98.9	166	1	AAP81514	Aap81514 Sequence
10	897	98.8	165	1	AAP94614	Aap94614 Human reg
11	884	97.4	166	8	ADQ29576	Adq29576 Human Reg
12	871	95.9	166	8	ADU20784	Adu20784 Human Reg
13	817	90.0	166	5	ABP69448	Abp69448 Human pol
14	817	90.0	166	8	ADS98793	Ads98793 Protein f
15	810	89.2	146	2	AAR66591	Aar66591 Human reg
16	810	89.2	147	2	AAR06425	Aar06425 Reg prote
17	799	88.0	144	2	AAR66592	Aar66592 Human reg
18	785	86.5	166	7	ADC78801	Adc78801 Human PRO
19	785	86.5	166	8	ADU20785	Adu20785 Human Reg
20	785	86.5	166	9	AEA04451	Aea04451 Human pro
21	785	86.5	166	10	AEF69882	Aef69882 Microsate
22	785	86.5	174	3	AAB54301	Aab54301 Human pan
23	745	82.0	133	2	AAR66593	Aar66593 Human reg
24	680	74.9	165	2	AAR34535	Aar34535 MUREG-1.
25	637	70.2	165	1	AAP94615	Aap94615 Rat reg p
26	635	69.9	165	1	AAP81513	Aap81513 Sequence
27	635	69.9	165	1	AAP83188	Aap83188 Sequence
28	635	69.9	165	2	AAR59289	Aar59289 Rat reg p
29	618.5	68.1	173	2	AAR34536	Aar34536 MUREG-2.
30	588.5	64.8	294	4	ABG01855	Abg01855 Novel hum
31	588.5	64.8	294	8	ADS98699	Ads98699 Protein f
32	588.5	64.8	406	4	ABG03060	Abg03060 Novel hum
33	588.5	64.8	406	8	ADS98701	Ads98701 Protein f
34	588.5	64.8	558	4	ABG00465	Abg00465 Novel hum
35	582	64.1	146	2	AAR66594	Aar66594 Rat reg p
36	571	62.9	144	2	AAR66595	Aar66595 Rat reg p
37	534	58.8	133	2	AAR66596	Aar66596 Rat reg p
38	517	56.9	132	8	ADO21124	Ado21124 Human car
39	513	56.5	240	4	ABG20353	Abg20353 Novel hum
40	465	51.2	117	6	ABR57096	Abr57096 MLHR comp
41	443.5	48.8	175	5	ABJ10605	Abj10605 Human nov
42	443.5	48.8	175	8	ADO09871	Ado09871 Human NOV
43	438.5	48.3	175	2	AAR57117	Aar57117 Human Pan
44	438.5	48.3	175	2	AAR54098	Aar54098 Mouse PAP
45	438.5	48.3	175	7	ADC78805	Adc78805 Human PRO

ALIGNMENTS

RESULT 1
AAR59288
ID AAR59288 standard; protein; 166 AA.
XX
AC AAR59288;

```
XX
DT   25-MAR-2003  (revised)
DT   03-FEB-1995  (first entry)
XX
DE   Human reg protein.
XX
KW   Human reg protein; blood sugar level depressant; hypoglycaemic agent;
KW   diabetes; hyperglycaemia; cell proliferation; islets of Langerhans.
XX
OS   Homo sapiens.
XX
FH   Key             Location/Qualifiers
FT   Peptide         21. .166
FT                   /note= "claimed subfragment"
FT   Peptide         23. .166
FT                   /note= "claimed subfragment"
FT   Peptide         34. .166
FT                   /note= "claimed subfragment"
XX
PN   WO9412203-A1.
XX
PD   09-JUN-1994.
XX
PF   01-DEC-1993;   93WO-JP001746.
XX
PR   01-DEC-1992;   92JP-00322121.
PR   19-APR-1993;   93JP-00091576.
XX
PA   (SHIO ) SHIONOGI SEIYAKU KK.
XX
PI   Okamoto H;
XX
DR   WPI; 1994-199962/24.
XX
PT   Sugar level depressants and cell proliferation agents comprising reg
PT   proteins - for treatment of diabetes, and inducing growth of islets of
PT   Langerhans.
XX
PS   Claim 1; Page 11; 20pp; Japanese.
XX
CC   Three specified subfragments of the human reg protein are claimed for use
CC   as blood sugar level depressants to treat diabetes. They are also useful
CC   to induce proliferation of cells in the islets of Langerhans. (Updated on
CC   25-MAR-2003 to correct PN field.)
XX
SQ   Sequence 166 AA;

  Query Match             100.0%;  Score 908;  DB 2;  Length 166;
  Best Local Similarity   100.0%;  Pred. No. 2.1e-80;
  Matches  166;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 MAQTSSYFMLISCLMFLSQSQGQEAQTELPQARISCPEGTNAYRSYCYYFNEDRETWVDA 60
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db          1 MAQTSSYFMLISCLMFLSQSQGQEAQTELPQARISCPEGTNAYRSYCYYFNEDRETWVDA 60

Qy         61 DLYCQNMNSGNLVSVLTQAEGAFVASLIKESGTDDFNVWIGLHDPKKNRRWHWSSGSLVS 120
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db         61 DLYCQNMNSGNLVSVLTQAEGAFVASLIKESGTDDFNVWIGLHDPKKNRRWHWSSGSLVS 120

Qy        121 YKSWGIGAPSSVNPGYCVSLTSSTGFQKWKDVPCEDKFSFVCKFKN 166
              ||||||||||||||||||||||||||||||||||||||||||||||
```



```
Db        121 YKSWGIGAPSSVNPGYCVSLTSSTGFQKWKDVPCEDKFSFVCKFKN 166


RESULT 2
AAB71653
ID   AAB71653 standard; protein; 166 AA.
XX
AC   AAB71653;
XX
DT   10-MAY-2001  (first entry)
XX
DE   Human colon associated protein #1.
XX
KW   Human; colon; cancer; disease.
XX
OS   Homo sapiens.
XX
PN   WO200112781-A1.
XX
PD   22-FEB-2001.
XX
PF   11-AUG-2000; 2000WO-US022157.
XX
PR   13-AUG-1999;   99US-0148680P.
XX
PA   (HUMA-) HUMAN GENOME SCI INC.
XX
PI   Birse CE,  Rosen CA;
XX
DR   WPI; 2001-147551/15.
XX
PT   Nucleic acids encoding 13 human colon cancer associated polypeptides,
PT   useful for preventing, diagnosing and/or treating e.g. cancers
PT   (especially colon cancer), Parkinson's disease and diabetic retinopathy.
XX
PS   Claim 11; Page 315-316; 326pp; English.
XX
CC   The present invention relates to 13 human colon cancer-associated
CC   proteins. These proteins and the nucleic acid encoding them may be used
CC   in the prevention, diagnosis and treatment of diseases associated with
CC   inappropriate colon cancer-associated protein expression
XX
SQ   Sequence 166 AA;

  Query Match             100.0%;  Score 908;  DB 4;  Length 166;
  Best Local Similarity   100.0%;  Pred. No. 2.1e-80;
  Matches  166;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 MAQTSSYFMLISCLMFLSQSQGQEAQTELPQARISCPEGTNAYRSYCYYFNEDRETWVDA 60
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db          1 MAQTSSYFMLISCLMFLSQSQGQEAQTELPQARISCPEGTNAYRSYCYYFNEDRETWVDA 60

Qy         61 DLYCQNMNSGNLVSVLTQAEGAFVASLIKESGTDDFNVWIGLHDPKKNRRWHWSSGSLVS 120
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db         61 DLYCQNMNSGNLVSVLTQAEGAFVASLIKESGTDDFNVWIGLHDPKKNRRWHWSSGSLVS 120

Qy        121 YKSWGIGAPSSVNPGYCVSLTSSTGFQKWKDVPCEDKFSFVCKFKN 166
              ||||||||||||||||||||||||||||||||||||||||||||||
Db        121 YKSWGIGAPSSVNPGYCVSLTSSTGFQKWKDVPCEDKFSFVCKFKN 166
```

```
RESULT 3
AAB71666
ID   AAB71666 standard; protein; 166 AA.
XX
AC   AAB71666;
XX
DT   10-MAY-2001  (first entry)
XX
DE   Human colon associated protein #14.
XX
KW   Human; colon; cancer; disease.
XX
OS   Homo sapiens.
XX
PN   WO200112781-A1.
XX
PD   22-FEB-2001.
XX
PF   11-AUG-2000; 2000WO-US022157.
XX
PR   13-AUG-1999;   99US-0148680P.
XX
PA   (HUMA-) HUMAN GENOME SCI INC.
XX
PI   Birse CE,  Rosen CA;
XX
DR   WPI; 2001-147551/15.
XX
PT   Nucleic acids encoding 13 human colon cancer associated polypeptides,
PT   useful for preventing, diagnosing and/or treating e.g. cancers
PT   (especially colon cancer), Parkinson's disease and diabetic retinopathy.
XX
PS   Claim 11; Page 322-323; 326pp; English.
XX
CC   The present invention relates to 13 human colon cancer-associated
CC   proteins. These proteins and the nucleic acid encoding them may be used
CC   in the prevention, diagnosis and treatment of diseases associated with
CC   inappropriate colon cancer-associated protein expression
XX
SQ   Sequence 166 AA;

  Query Match            100.0%;  Score 908;  DB 4;  Length 166;
  Best Local Similarity   100.0%;  Pred. No. 2.1e-80;
  Matches  166;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 MAQTSSYFMLISCLMFLSQSQGQEAQTELPQARISCPEGTNAYRSYCYYFNEDRETWVDA 60
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db          1 MAQTSSYFMLISCLMFLSQSQGQEAQTELPQARISCPEGTNAYRSYCYYFNEDRETWVDA 60

Qy         61 DLYCQNMNSGNLVSVLTQAEGAFVASLIKESGTDDFNVWIGLHDPKKNRRWHWSSGSLVS 120
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db         61 DLYCQNMNSGNLVSVLTQAEGAFVASLIKESGTDDFNVWIGLHDPKKNRRWHWSSGSLVS 120

Qy        121 YKSWGIGAPSSVNPGYCVSLTSSTGFQKWKDVPCEDKFSFVCKFKN 166
              ||||||||||||||||||||||||||||||||||||||||||||||
Db        121 YKSWGIGAPSSVNPGYCVSLTSSTGFQKWKDVPCEDKFSFVCKFKN 166


RESULT 4
ADQ29578
ID   ADQ29578 standard; protein; 166 AA.
```



```
XX
AC   ADQ29578;
XX
DT   07-OCT-2004  (first entry)
XX
DE   Human Reg1-alpha protein #2.
XX
KW   human; colon cancer; TIMP1; Reg1-alpha;
KW   colorectal cancer-associated marker.
XX
OS   Homo sapiens.
XX
PN   EP1439393-A2.
XX
PD   21-JUL-2004.
XX
PF   15-DEC-2003; 2003EP-00257868.
XX
PR   13-DEC-2002; 2002US-0433554P.
PR   31-JUL-2003; 2003US-0491397P.
XX
PA   (FARB ) BAYER HEALTHCARE LLC.
PA   (MAYO-) MAYO FOUND MEDICAL EDUCATION & RES.
XX
PI   Astle JH,  Boardman LA,  Bugart LJ,  Burgess CC,  Catino TJ;
PI   Dwivedi P,  Huntress M,  Johnson KA,  Lewis ME,  Maimonis PJ,  Myerow SH;
PI   Brown-Shimer SLA,  Thiagalingam A,  Thibodeau SN,  Molino GA;
XX
DR   WPI; 2004-545561/53.
DR   N-PSDB; ADQ29577.
XX
PT   Diagnosing colon cancer in individual, preferably human, by detecting
PT   presence of TIMP 1 in sample, where presence of TIMP 1 in sample is
PT   indicative of colon cancer in individual.
XX
PS   Claim 7; SEQ ID NO 4; 433pp; English.
XX
CC   The invention comprises a method for diagnosing colon cancer in an
CC   individual, the method involves obtaining a serum sample from the
CC   individual and detecting the presence of either TIMP1 or Reg1-alpha and
CC   an additional colorectal cancer-associated marker. The method of the
CC   invention is useful for diagnosing colon cancer in an individual. The
CC   present amino acid sequence represents a human Reg1-alpha protein of the
CC   invention.
XX
SQ   Sequence 166 AA;

  Query Match            100.0%;  Score 908;  DB 8;  Length 166;
  Best Local Similarity   100.0%;  Pred. No. 2.1e-80;
  Matches  166;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 MAQTSSYFMLISCLMFLSQSQGQEAQTELPQARISCPEGTNAYRSYCYYFNEDRETWVDA 60
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db          1 MAQTSSYFMLISCLMFLSQSQGQEAQTELPQARISCPEGTNAYRSYCYYFNEDRETWVDA 60

Qy         61 DLYCQNMNSGNLVSVLTQAEGAFVASLIKESGTDDFNVWIGLHDPKKNRRWHWSSGSLVS 120
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db         61 DLYCQNMNSGNLVSVLTQAEGAFVASLIKESGTDDFNVWIGLHDPKKNRRWHWSSGSLVS 120

Qy        121 YKSWGIGAPSSVNPGYCVSLTSSTGFQKWKDVPCEDKFSFVCKFKN 166
              ||||||||||||||||||||||||||||||||||||||||||||||
```

```
Db        121 YKSWGIGAPSSVNPGYCVSLTSSTGFQKWKDVPCEDKFSFVCKFKN 166


RESULT 5
ADQ60160
ID   ADQ60160 standard; protein; 166 AA.
XX
AC   ADQ60160;
XX
DT   07-OCT-2004  (first entry)
XX
DE   Human regenerating islet-derived 1 alpha (REG Ialpha) protein.
XX
KW   inflammatory bowel disease; IBD; antiinflammatory; antiulcer;
KW   gastrointestinal; ulcerative colitis; Crohn's disease; human;
KW   regenerating islet-derived 1 alpha; REG Ialpha; receptor.
XX
OS   Homo sapiens.
XX
PN   JP2004194534-A.
XX
PD   15-JUL-2004.
XX
PF   17-DEC-2002; 2002JP-00365079.
XX
PR   17-DEC-2002; 2002JP-00365079.
XX
PA   (SUMU ) SUMITOMO SEIYAKU KK.
XX
DR   WPI; 2004-537122/52.
DR   N-PSDB; ADQ60157.
XX
PT   New markers of inflammatory bowel disease comprise at least 15 base pairs
PT   of the glucose-dependent insulinotropic polypeptide receptor, granulocyte
PT   colony-stimulating factor receptor, or regenerating islet-derived 1 alpha
PT   genes.
XX
PS   Example 3; SEQ ID NO 6; 57pp; Japanese.
XX
CC   The invention relates to a novel marker of inflammatory bowel disease
CC   (IBD) which comprises a polynucleotide having at least 15 contiguous
CC   bases of the base sequence of the glucose-dependent insulinotropic
CC   polypeptide receptor (GIPR) gene, granulocyte colony-stimulating factor
CC   receptor (GCSFR) gene or regenerating islet-derived 1 alpha (REG Ialpha)
CC   gene. The marker of the invention demonstrates antiinflammatory,
CC   antiulcer and gastrointestinal activities and may be useful as a probe or
CC   primer in the detection and subsequent treatment of inflammatory bowel
CC   disease and other conditions such as ulcerative colitis and Crohn's
CC   disease. The current sequence is that of the human regenerating islet-
CC   derived 1 alpha (REG Ialpha) protein of the invention.
XX
SQ   Sequence 166 AA;

  Query Match             100.0%;  Score 908;  DB 8;  Length 166;
  Best Local Similarity   100.0%;  Pred. No. 2.1e-80;
  Matches  166;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 MAQTSSYFMLISCLMFLSQSQGQEAQTELPQARISCPEGTNAYRSYCYYFNEDRETWVDA 60
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db          1 MAQTSSYFMLISCLMFLSQSQGQEAQTELPQARISCPEGTNAYRSYCYYFNEDRETWVDA 60
```



```
Qy         61 DLYCQNMNSGNLVSVLTQAEGAFVASLIKESGTDDFNVWIGLHDPKKNRRWHWSSGSLVS 120
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db         61 DLYCQNMNSGNLVSVLTQAEGAFVASLIKESGTDDFNVWIGLHDPKKNRRWHWSSGSLVS 120

Qy        121 YKSWGIGAPSSVNPGYCVSLTSSTGFQKWKDVPCEDKFSFVCKFKN 166
              ||||||||||||||||||||||||||||||||||||||||||||||
Db        121 YKSWGIGAPSSVNPGYCVSLTSSTGFQKWKDVPCEDKFSFVCKFKN 166


RESULT 6
ADS97994
ID   ADS97994 standard; protein; 166 AA.
XX
AC   ADS97994;
XX
DT   30-DEC-2004  (first entry)
XX
DE   Protein factor discovery related isolated human polypeptide, SEQ ID 258.
XX
KW   antiinflammatory; cytostatic; antimicrobial; gene therapy; inflammation;
KW   leukaemia; nervous system disorder; infection.
XX
OS   Homo sapiens.
XX
PN   WO2004087874-A2.
XX
PD   14-OCT-2004.
XX
PF   24-MAR-2004; 2004WO-US009202.
XX
PR   28-MAR-2003; 2003US-0458824P.
XX
PA   (NUVE-) NUVELO INC.
PA   (DRMA/) DRMANAC R T.
XX
PI   Tang YT,  Zhou P,  Wang J,  Wang ZW,  Hu T;
XX
DR   WPI; 2004-737686/72.
DR   N-PSDB; ADS97759.
XX
PT   New polynucleotides encoding a polypeptide with biological activity,
PT   useful for treating inflammation, leukemias, nervous system disorders, or
PT   infections.
XX
PS   Claim 20; SEQ ID NO 258; 253pp; English.
XX
CC   The invention relates to a novel isolated polynucleotide comprising any
CC   of the 235 nucleotide sequences described in the specification. The
CC   invention further comprises: an isolated polynucleotide encoding a
CC   polypeptide with biological activity, where the polynucleotide hybridizes
CC   to one of the 235 novel polynucleotides under stringent hybridization
CC   conditions, or having greater than about 99% sequence identity with the
CC   novel polynucleotide; a vector comprising a novel polynucleotide; an
CC   expression vector comprising the novel polynucleotide; a host cell
CC   genetically engineered to comprise the novel polynucleotide, which can be
CC   operatively associated with a regulatory sequence that modulates
CC   expression of the polynucleotide in the host cell; an isolated
CC   polypeptide encoded by the novel polynucleotide, or a polynucleotide
CC   hybridizing under stringent conditions to the novel polynucleotide; a
CC   composition comprising the polypeptide and a carrier; an antibody
CC   directed against the polypeptide; a method for detecting the novel
```

```
CC   polynucleotide in a sample; a method for detecting the polypeptide in a
CC   sample; a method for identifying a compound that binds to the polypeptide
CC   ; a method for producing the polypeptide; an isolated polypeptide
CC   comprising any of the 235 amino acid sequences described in the
CC   specification; and a collection of polynucleotides comprising of at least
CC   one of the polynucleotides cited above. The polypeptides and
CC   polynucleotides of the invention have antiinflammatory, cytostatic, and
CC   antimicrobial activities. The novel polynucleotide may be used to treat
CC   disorders by gene therapy. The polypeptides and polynucleotides are
CC   useful for treating inflammation, leukaemias, nervous system disorders,
CC   or infections. This sequence represents one of the 235 novel isolated
CC   polypeptides of the invention.
XX
SQ   Sequence 166 AA;

  Query Match             100.0%;  Score 908;  DB 8;  Length 166;
  Best Local Similarity   100.0%;  Pred. No. 2.1e-80;
  Matches  166;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 MAQTSSYFMLISCLMFLSQSQGQEAQTELPQARISCPEGTNAYRSYCYYFNEDRETWVDA 60
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db          1 MAQTSSYFMLISCLMFLSQSQGQEAQTELPQARISCPEGTNAYRSYCYYFNEDRETWVDA 60

Qy         61 DLYCQNMNSGNLVSVLTQAEGAFVASLIKESGTDDFNVWIGLHDPKKNRRWHWSSGSLVS 120
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db         61 DLYCQNMNSGNLVSVLTQAEGAFVASLIKESGTDDFNVWIGLHDPKKNRRWHWSSGSLVS 120

Qy        121 YKSWGIGAPSSVNPGYCVSLTSSTGFQKWKDVPCEDKFSFVCKFKN 166
              ||||||||||||||||||||||||||||||||||||||||||||||
Db        121 YKSWGIGAPSSVNPGYCVSLTSSTGFQKWKDVPCEDKFSFVCKFKN 166


RESULT 7
AEA04450
ID   AEA04450 standard; protein; 166 AA.
XX
AC   AEA04450;
XX
DT   28-JUL-2005  (first entry)
XX
DE   Human protein from gene overexpressed in cancer, REG1A.
XX
KW   Tumor marker; colon tumor; cancer; cytostatic; neoplasm; diagnostic;
KW   microarray; drug screening.
XX
OS   Homo sapiens.
XX
PN   WO2005044990-A2.
XX
PD   19-MAY-2005.
XX
PF   01-NOV-2004; 2004WO-US036404.
XX
PR   04-NOV-2003; 2003US-00700439.
XX
PA   (FARB ) BAYER HEALTHCARE LLC.
PA   (MAYO-) MAYO FOUND MEDICAL EDUCATION & RES.
XX
PI   Burgess C,  Myerow S,  Thiagalingam A,  Maimonis P,  Molino G;
PI   Burgart L,  Boardman LA,  Thibodeau S,  Lewis M;
XX
```



```
DR   WPI; 2005-372198/38.
DR   N-PSDB; AEA04357.
DR   REFSEQ; NP_002900.
XX
PT   Detecting expression of one or more nucleic acid sequences in biological
PT   sample, useful for detecting cancer, comprises detecting a change in the
PT   expression level of one or more nucleic acid sequences relative to a
PT   control expression level.
XX
PS   Claim 20; SEQ ID NO 95; 256pp; English.
XX
CC   The invention relates to detecting differential expression of one or more
CC   nucleic acid sequences (appearing as AEA04356-AEA04448 in a biological
CC   sample comprising obtaining the sample from a subject, and detecting a
CC   change in the expression level of one or more nucleic acid sequences
CC   relative to a control expression level of the nucleic acid sequences, is
CC   new. Also included are detecting cancer (or a pre-malignant condition
CC   thereof) in a subject (comprising comparing the expression level of one
CC   or more nucleic acid sequences in a biological sample from the subject
CC   with a control expression level of the nucleic acid sequences, where a
CC   change of at least two-fold in the expression level of the nucleic acid
CC   sequences is indicative of cancer or pre-malignant condition), monitoring
CC   the onset (or progression, or regression) of cancer (or a pre-malignant
CC   condition) in a subject (by detecting in a biological sample of the
CC   subject at a first point in time the expression of one or more nucleic
CC   acid sequences, repeating the first step at a subsequent point in time
CC   and comparing the expression level detected, where a change in the
CC   expression level is indicative of progression of cancer or its pre-
CC   malignant condition in the subject), determining prognosis for cancer or
CC   its pre-malignant condition in a subject (comprising detecting in a
CC   biological sample of the subject, the expression level of one or more
CC   nucleic acid sequences, comparing the expression level with a reference
CC   expression level of the nucleic acid sequences and evaluating the
CC   prognosis of the subject based on the comparison), determining the
CC   efficacy of a test compound for inhibiting cancer in a subject,
CC   determining the efficacy of a therapy for inhibiting cancer in a subject,
CC   selecting a composition for inhibiting cancer in a subject, inhibiting
CC   cancer in a subject, a polypeptide encoded by the nucleic acids above
CC   (appearing as AEA04449-AEA04541), an antibody that specifically binds to
CC   the polypeptide sequence, and detecting in a biological sample the
CC   presence of a polypeptide. The method is useful for detecting
CC   differential expression of one or more nucleic acid sequences in a
CC   biological sample, which is useful for detecting cancer (especially colon
CC   cancer), monitoring the onset, progression, or regression of cancer or a
CC   pre-malignant condition, or determining prognosis for cancer or its pre-
CC   malignant condition in a subject, or for determining the efficacy of a
CC   test compound for inhibiting cancer in a subject. The compound is useful
CC   for inhibiting cancer in a subject. The antibodies may also be used to
CC   treat cancer. The present sequence is a protein from a human gene over-
CC   expressed in cancer samples.
XX
SQ   Sequence 166 AA;

  Query Match             100.0%;  Score 908;  DB 9;  Length 166;
  Best Local Similarity   100.0%;  Pred. No. 2.1e-80;
  Matches  166;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 MAQTSSYFMLISCLMFLSQSQGQEAQTELPQARISCPEGTNAYRSYCYYFNEDRETWVDA 60
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db          1 MAQTSSYFMLISCLMFLSQSQGQEAQTELPQARISCPEGTNAYRSYCYYFNEDRETWVDA 60
```

```
Qy          61 DLYCQNMNSGNLVSVLTQAEGAFVASLIKESGTDDFNVWIGLHDPKKNRRWHWSSGSLVS 120
               ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db          61 DLYCQNMNSGNLVSVLTQAEGAFVASLIKESGTDDFNVWIGLHDPKKNRRWHWSSGSLVS 120

Qy         121 YKSWGIGAPSSVNPGYCVSLTSSTGFQKWKDVPCEDKFSFVCKFKN 166
               ||||||||||||||||||||||||||||||||||||||||||||||
Db         121 YKSWGIGAPSSVNPGYCVSLTSSTGFQKWKDVPCEDKFSFVCKFKN 166


RESULT 8
AAB43737
ID   AAB43737 standard; protein; 174 AA.
XX
AC   AAB43737;
XX
DT   08-FEB-2001  (first entry)
XX
DE   Human cancer associated protein sequence SEQ ID NO:1182.
XX
KW   Human; cancer associated gene; cancer antigen; detection; cancer;
KW   diagnosis; cytostatic; proliferative; vulnerary; immunomodulator;
KW   antidiabetic; antiasthmatic; antirheumatic; antiarthritic; antiviral;
KW   antiinflammatory; antithyroid; antiallergic; antibacterial; cardiant;
KW   dermatological; neuroprotective; thrombolytic; coagulant; nootropic;
KW   vasotropic; antipsoriatic; antiangiogenic; gene therapy; inflammation;
KW   immune disorder; haematopoietic cell disorder; autoimmune disorder;
KW   allergic reaction; graft versus host disease; organ rejection;
KW   haemostatic; thrombolytic; cardiovascular disorder; infection;
KW   neurological disease; drug screening.
XX
OS   Homo sapiens.
XX
PN   WO200055350-A1.
XX
PD   21-SEP-2000.
XX
PF   08-MAR-2000; 2000WO-US005882.
XX
PR   12-MAR-1999;   99US-0124270P.
XX
PA   (HUMA-) HUMAN GENOME SCI INC.
XX
PI   Rosen CA,  Ruben SM;
XX
DR   WPI; 2000-587533/55.
DR   N-PSDB; AAC77946.
XX
PT   Novel isolated nucleic acids comprising sequences encoding peptides
PT   useful for treating or diagnosing e.g. cancer.
XX
PS   Claim 11; Page 1805-1806; 2352pp; English.
XX
CC   AAC77607 to AAC78448 encode the human cancer associated proteins given in
CC   AAB43398 to AAB44239. The proteins can have activities based on the
CC   tissues and cells the genes are expressed in. Example of activities
CC   include: cytostatic; proliferative; vulnerary; immunomodulator;
CC   antidiabetic; antiasthmatic; antirheumatic; antiarthritic;
CC   antiinflammatory; antithyroid; antiallergic; antibacterial; antiviral;
CC   dermatological; neuroprotective; cardiant; thrombolytic; coagulant;
CC   nootropic; vasotropic; antipsoriatic and antiangiogenic. The
CC   polynucleotides and polypeptides can be used for preventing, treating or
```



```
CC   ameliorating medical conditions and diagnosing pathological conditions.
CC   Polynucleotides, polypeptides, antibodies, agonists and antagonists from
CC   the present invention may be used to treat immune disorders by activating
CC   or inhibiting the proliferation, differentiation or mobilisation of
CC   immune cells, to treat disorders of haematopoietic cells, autoimmune
CC   disorders, allergic reactions, graft versus host disease and organ
CC   rejection, modulate haemostatic or thrombolytic activity, modulate
CC   inflammation, cancers, cardiovascular disorders, neurological disease and
CC   bacterial or viral infections. The peptides, nucleotides, antibodies,
CC   agonists and antagonists may be also be used in drug screens. AAC78449 to
CC   AAC78457 and AAB44240 represent sequences used in the exemplification of
CC   the present invention
XX
SQ   Sequence 174 AA;

  Query Match             100.0%;  Score 908;  DB 3;  Length 174;
  Best Local Similarity   100.0%;  Pred. No. 2.2e-80;
  Matches  166;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 MAQTSSYFMLISCLMFLSQSQGQEAQTELPQARISCPEGTNAYRSYCYYFNEDRETWVDA 60
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db          9 MAQTSSYFMLISCLMFLSQSQGQEAQTELPQARISCPEGTNAYRSYCYYFNEDRETWVDA 68

Qy         61 DLYCQNMNSGNLVSVLTQAEGAFVASLIKESGTDDFNVWIGLHDPKKNRRWHWSSGSLVS 120
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db         69 DLYCQNMNSGNLVSVLTQAEGAFVASLIKESGTDDFNVWIGLHDPKKNRRWHWSSGSLVS 128

Qy        121 YKSWGIGAPSSVNPGYCVSLTSSTGFQKWKDVPCEDKFSFVCKFKN 166
              ||||||||||||||||||||||||||||||||||||||||||||||
Db        129 YKSWGIGAPSSVNPGYCVSLTSSTGFQKWKDVPCEDKFSFVCKFKN 174


RESULT 9
AAP81514
ID   AAP81514 standard; protein; 166 AA.
XX
AC   AAP81514;
XX
DT   25-MAR-2003  (revised)
DT   02-FEB-1991  (first entry)
XX
DE   Sequence encoded by human reg cDNA.
XX
KW   Pancreatic islet B cell regeneration; diabetes; therapy.
XX
OS   Homo sapiens.
XX
PN   EP286114-A.
XX
PD   12-OCT-1988.
XX
PF   08-APR-1988;   88EP-00105623.
XX
PR   09-APR-1987;   87JP-00087807.
PR   10-AUG-1987;   87JP-00200514.
PR   24-MAR-1988;   88JP-00071671.
PR   04-AUG-1988;   88JP-00195727.
PR   09-AUG-1988;   88EP-00112942.
XX
PA   (SHIO ) SHIONOGI SEIYAKU KK.
XX
```

```
PI   Okamoto H;
XX
DR   WPI; 1988-287314/41.
DR   N-PSDB; AAN81962.
XX
PT   Rat and human reg genes - used for producing proteins for regeneration of
PT   insulin-producing pancreatic B cells of patients with diabetes.
XX
PS   Disclosure; Fig 3; 12pp; English.
XX
CC   The reg gene is specifically expressed in regenerating pancreatic islet B
CC   cells. A gene hybridising to a probe corresponding to at least a part of
CC   the whole base sequence of rat reg gene or human reg gene is claimed. By
CC   mass producing the proteins encoded by the gene it may be possible to
CC   open a new dimension in the treatment of diabetes (Updated on 25-MAR-2003
CC   to correct PD field.) (Updated on 25-MAR-2003 to correct PR field.)
XX
SQ   Sequence 166 AA;

  Query Match             98.9%;  Score 898;  DB 1;  Length 166;
  Best Local Similarity   98.8%;  Pred. No. 2e-79;
  Matches  164;  Conservative    1;  Mismatches    1;  Indels    0;  Gaps    0;

Qy          1 MAQTSSYFMLISCLMFLSQSQGQEAQTELPQARISCPEGTNAYRSYCYYFNEDRETWVDA 60
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db          1 MAQTSSYFMLISCLMFLSQSQGQEAQTELPQARISCPEGTNAYRSYCYYFNEDRETWVDA 60

Qy         61 DLYCQNMNSGNLVSVLTQAEGAFVASLIKESGTDDFNVWIGLHDPKKNRRWHWSSGSLVS 120
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db         61 DLYCQNMNSGNLVSVLTQAEGAFVASLIKESGTDDFNVWIGLHDPKKNRRWHWSSGSLVS 120

Qy        121 YKSWGIGAPSSVNPGYCVSLTSSTGFQKWKDVPCEDKFSFVCKFKN 166
              |||||||||||||||||||||||| |||||||||:||||||||||
Db        121 YKSWGIGAPSSVNPGYCVSLTSSTGLQKWKDVPCEEKFSFVCKFKN 166


RESULT 10
AAP94614
ID   AAP94614 standard; protein; 165 AA.
XX
AC   AAP94614;
XX
DT   25-MAR-2003  (revised)
DT   21-JUN-1990  (first entry)
XX
DE   Human reg protein.
XX
KW   reg proteins; islet cells; diabetes; insulin; ds.
XX
OS   Homo sapiens.
XX
PN   EP303233-A.
XX
PD   15-FEB-1989.
XX
PF   09-AUG-1988;   88EP-00112942.
XX
PR   10-AUG-1987;   87JP-00200514.
XX
PA   (SHIO ) SHIONOGI & CO LTD.
XX
```



```
PI   Okamoto H,  Itoh T,  Teraoka H,  Tsuzuki H,  Yoshida M;
XX
DR   WPI; 1989-048048/07.
DR   N-PSDB; AAP94614.
XX
PT   New human reg proteins - useful for regenerating islet B cells in
PT   diabetes treatment.
XX
PS   Claim 1; Fig 1; 19pp; English.
XX
CC   Protein product for reg gene useful in regeneration of human pancreatic
CC   islet B cells in treatment of diabetes. Derivatives from bases 21(Gly),
CC   22(Gln), 23(Glu), 24(Ala), 25(Gln), 30(Gln), 31(Ala) and 33(Ile) to
CC   165(Asn) are also functional. (Updated on 25-MAR-2003 to correct PA
CC   field.) (Updated on 25-MAR-2003 to correct PI field.)
XX
SQ   Sequence 165 AA;

  Query Match             98.8%;  Score 897;  DB 1;  Length 165;
  Best Local Similarity   99.4%;  Pred. No. 2.5e-79;
  Matches  164;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy          2 AQTSSYFMLISCLMFLSQSQGQEAQTELPQARISCPEGTNAYRSYCYYFNEDRETWVDAD 61
              |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db          1 AQTSSYFMLISCLMFLSQSQGQEAQTELPQARISCPEGTNAYRSYCYYFNEDRETWVDAD 60

Qy         62 LYCQNMNSGNLVSVLTQAEGAFVASLIKESGTDDFNVWIGLHDPKKNRRWHWSSGSLVSY 121
              |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db         61 LYCQNMNSGNLVSVLTQAEGAFVASLIKESGTDDFNVWIGLHDPKKNRRWHWSSGSLVSY 120

Qy        122 KSWGIGAPSSVNPGYCVSLTSSTGFQKWKDVPCEDKFSFVCKFKN 166
              |||||||||||||||||||||||| |||||||||||||||||||||
Db        121 KSWGIGAPSSVNPGYCVSLTSSTGLQKWKDVPCEDKFSFVCKFKN 165


RESULT 11
ADQ29576
ID   ADQ29576 standard; protein; 166 AA.
XX
AC   ADQ29576;
XX
DT   07-OCT-2004  (first entry)
XX
DE   Human Regl-alpha protein #1.
XX
KW   human; colon cancer; TIMP1; Regl-alpha;
KW   colorectal cancer-associated marker.
XX
OS   Homo sapiens.
XX
PN   EP1439393-A2.
XX
PD   21-JUL-2004.
XX
PF   15-DEC-2003; 2003EP-00257868.
XX
PR   13-DEC-2002; 2002US-0433554P.
PR   31-JUL-2003; 2003US-0491397P.
XX
PA   (FARB ) BAYER HEALTHCARE LLC.
PA   (MAYO-) MAYO FOUND MEDICAL EDUCATION & RES.
```

```
XX
PI   Astle JH,  Boardman LA,  Bugart LJ,  Burgess CC,  Catino TJ;
PI   Dwivedi P,  Huntress M,  Johnson KA,  Lewis ME,  Maimonis PJ,  Myerow SH;
PI   Brown-Shimer SLA,  Thiagalingam A,  Thibodeau SN,  Molino GA;
XX
DR   WPI; 2004-545561/53.
DR   N-PSDB; ADQ29575.
XX
PT   Diagnosing colon cancer in individual, preferably human, by detecting
PT   presence of TIMP 1 in sample, where presence of TIMP 1 in sample is
PT   indicative of colon cancer in individual.
XX
PS   Claim 7; SEQ ID NO 2; 433pp; English.
XX
CC   The invention comprises a method for diagnosing colon cancer in an
CC   individual, the method involves obtaining a serum sample from the
CC   individual and detecting the presence of either TIMP1 or Reg1-alpha and
CC   an additional colorectal cancer-associated marker. The method of the
CC   invention is useful for diagnosing colon cancer in an individual. The
CC   present amino acid sequence represents a human Reg1-alpha protein of the
CC   invention.
XX
SQ   Sequence 166 AA;

  Query Match             97.4%;  Score 884;  DB 8;  Length 166;
  Best Local Similarity   97.6%;  Pred. No. 4.7e-78;
  Matches  162;  Conservative    2;  Mismatches    2;  Indels    0;  Gaps    0;

Qy          1 MAQTSSYFMLISCLMFLSQSQGQEAQTELPQARISCPEGTNAYRSYCYYFNEDRETWVDA 60
              ||||:|:||||| ||||| ||||||||||||||||||||||||||||||||||||||||
Db          1 MAQTNSFFMLISSLMFLSLSQGQEAQTELPQARISCPEGTNAYRSYCYYFNEDRETWVDA 60

Qy         61 DLYCQNMNSGNLVSVLTQAEGAFVASLIKESGTDDFNVWIGLHDPKKNRRWHWSSGSLVS 120
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db         61 DLYCQNMNSGNLVSVLTQAEGAFVASLIKESGTDDFNVWIGLHDPKKNRRWHWSSGSLVS 120

Qy        121 YKSWGIGAPSSVNPGYCVSLTSSTGFQKWKDVPCEDKFSFVCKFKN 166
              ||||||||||||||||||||||||||||||||||||||||||||||
Db        121 YKSWGIGAPSSVNPGYCVSLTSSTGFQKWKDVPCEDKFSFVCKFKN 166


RESULT 12
ADU20784
ID   ADU20784 standard; protein; 166 AA.
XX
AC   ADU20784;
XX
DT   13-JAN-2005  (first entry)
XX
DE   Human RegIalpha polypeptide, SEQ ID 1.
XX
KW   RegIalpha; RegIbeta; RegIII; RegIV; EXTL3; tumour; Reg signaling;
KW   pro-apoptosis; human.
XX
OS   Homo sapiens.
XX
PN   WO2004092352-A2.
XX
PD   28-OCT-2004.
XX
PF   14-APR-2004; 2004WO-US009286.
```



```
XX
PR   14-APR-2003; 2003US-0462317P.
PR   08-APR-2004; 2004US-00819991.
XX
PA   (UNIW ) UNIV WASHINGTON.
XX
PI   Dieckgraefe BK,  Korzenik JR;
XX
DR   WPI; 2004-766858/75.
XX
PT   New methods comprising delivering to a tumor cell an antisense construct
PT   comprising at least 15 nucleotides of the complement of a rat, mouse or
PT   human Reg gene family cDNA, useful for disrupting Reg signaling pathway.
XX
PS   Disclosure; Fig 2; 75pp; English.
XX
CC   The invention relates to a method that involves delivering to a tumour
CC   cell an antisense construct comprising at least 15 nucleotides of the
CC   complement of a rat, mouse or human Reg gene family cDNA selected from
CC   RegIalpha, RegIbeta, RegIII, RegIV, and EXTL3, where the tumour cell
CC   expresses an mRNA molecule that is complementary to native mRNA of the
CC   Reg gene. A COX-2 inhibitor, a chemotherapeutic drug and radiation is
CC   also administered to the tumour cell. This method also comprises
CC   administering to a tumour cell an RNA interference construct comprising
CC   at least 19 nucleotides of a rat, mouse, or human Reg gene family cDNA.
CC   The RNA interference construct encodes a small hairpin RNA. The RNA
CC   interference construct encodes each strand of an interference RNA duplex
CC   under the control of a separate promoter. The RNA interference construct
CC   contains an inverted repeat of the Reg family gene cDNA. The method
CC   alternatively comprises delivering to a tumour cell siRNA comprising 19-
CC   21 bp duplexes of a rat, mouse or human Reg gene family RNA, where the
CC   siRNA comprises 2 nt 3' overhangs, where the Reg gene mRNA produced by
CC   the tumour cell is cleaved. The method can comprise contacting a rat,
CC   mouse or human EXTL3 protein and a rat, mouse, or human Reg protein, in
CC   the presence or absence of a test substance; determining binding of the
CC   Reg protein to the EXTL3 protein in the presence and in the absence of a
CC   test compound; and identifying a test substance, which inhibits binding
CC   of the Reg protein to the EXTL3 protein. The method can also comprise
CC   delivering an inhibitor of binding of, or an antibody that binds to a
CC   rat, mouse, or human EXTL3 protein to a rat, mouse, or human Reg protein.
CC   The methods are useful for disrupting Reg signaling pathway to permit
CC   spontaneous and therapeutic induction of pro-apoptotic signals to be more
CC   effective. The present sequence represents a human RegIalpha polypeptide.
XX
SQ   Sequence 166 AA;

  Query Match             95.9%;  Score 871;  DB 8;  Length 166;
  Best Local Similarity   96.4%;  Pred. No. 8.8e-77;
  Matches  160;  Conservative    2;  Mismatches    4;  Indels    0;  Gaps    0;

Qy          1 MAQTSSYFMLISCLMFLSQSQGQEAQTELPQARISCPEGTNAYRSYCYYFNEDRETWVDA 60
              ||||:|:||||| ||||| |||||||||||||||||||||||| ||||||||||
Db          1 MAQTNSFFMLISSLMFLSLSQGQEAQTELPQARISCPEGTNAYRSYCYVFNEDRETWVDA 60

Qy         61 DLYCQNMNSGNLVSVLTQAEGAFVASLIKESGTDDFNVWIGLHDPKKNRRWHWSSGSLVS 120
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db         61 DLYCQNMNSGNLVSVLTQAEGAFVASLIKESGTDDFNVWIGLHDPKKNRRWHWSSGSLVS 120

Qy        121 YKSWGIGAPSSVNPGYCVSLTSSTGFQKWKDVPCEDKFSFVCKFKN 166
              ||||| ||||||||||||||||||||||||||||||||||||||||
Db        121 YKSWGTGAPSSVNPGYCVSLTSSTGFQKWKDVPCEDKFSFVCKFKN 166
```

```
RESULT 13
ABP69448
ID   ABP69448 standard; protein; 166 AA.
XX
AC   ABP69448;
XX
DT   20-JAN-2003  (first entry)
XX
DE   Human polypeptide SEQ ID NO 1495.
XX
KW   Human; genome mapping; gene therapy; food supplement; virus; fungus;
KW   cell-proliferative disorder; neurodegenerative disease; bacterial;
KW   Parkinson's disease; Alzheimer's disease; autoimmune disease;
KW   multiple sclerosis; diabetes; genetic disorder; wound; burn; infection;
KW   arthritis; cytostatic; immunomodulator; nootropic; neuroprotective;
KW   antiparkinsonian; antidiabetic; immunosuppressive; dermatological;
KW   haemostatic; vulnerary; fungicide; antibacterial; virucide; protozoacide;
KW   antiarthritic.
XX
OS   Homo sapiens.
XX
PN   WO200270539-A2.
XX
PD   12-SEP-2002.
XX
PF   05-MAR-2002; 2002WO-US005095.
XX
PR   05-MAR-2001; 2001US-00799451.
XX
PA   (HYSE-) HYSEQ INC.
XX
PI   Tang YT,  Zhou P,  Goodrich RW,  Asundi V,  Zhang J,  Zhao QA,  Ren F;
PI   Xue AJ,  Yang Y,  Ma Y,  Yamazaki V,  Chen R,  Wang Z,  Ghosh M;
PI   Wehrman T,  Wang J,  Wang D,  Drmanac RT;
XX
DR   WPI; 2002-759812/82.
DR   N-PSDB; ABZ11665.
XX
PT   New polynucleotides comprising sequences assembled from expressed
PT   sequence tags (ESTs), useful for treating cell-proliferative,
PT   neurodegenerative, autoimmune, genetic, myeloid or lymphoid, or platelet
PT   or coagulation disorders.
XX
PS   Claim 9; SEQ ID NO 1495; 1012pp + Sequence Listing; English.
XX
CC   The invention relates to an isolated polynucleotide (I) comprising a
CC   nucleotide sequence selected from any of 948 sequences (ABZ11119-
CC   ABZ12066) or their mature protein coding portion, active domain coding
CC   protein or complementary sequences. The polynucleotides are useful for
CC   identifying expressed genes or for physical mapping of human genome. The
CC   encoded polypeptides (ABP68902-ABP69849) are useful as molecular weight
CC   markers, as a food supplement, for generating antibodies, in medical
CC   imaging, screening and diagnostic assays and for treating cell-
CC   proliferative disorders (cancer), neurodegenerative diseases (Parkinson's
CC   or Alzheimer's disease), autoimmune diseases (multiple sclerosis,
CC   diabetes, lupus) genetic disorders, myeloid or lymphoid disorders,
CC   platelet or coagulation disorders, wound, burns, incision, ulcers, liver
CC   or lung fibrosis, infections (bacterial, viral, fungal, parasitic),
CC   arthritis, etc. Note: The sequence data for this patent did not form part
```



```
CC   of the printed specification, but was obtained in electronic format
CC   directly from WIPO at ftp.wipo.int/pub/published_pct_sequences
XX
SQ   Sequence 166 AA;

  Query Match             90.0%;  Score 817;  DB 5;  Length 166;
  Best Local Similarity   89.8%;  Pred. No. 1.7e-71;
  Matches  149;  Conservative    7;  Mismatches   10;  Indels    0;  Gaps    0;

Qy          1 MAQTSSYFMLISCLMFLSQSQGQEAQTELPQARISCPEGTNAYRSYCYYFNEDRETWVDA 60
              || | ||||| |||||| || ||:||||:|:|||:|||: | ||||||||:: |||| ||
Db          1 MAHTRSYFMLNSCLMFLPQSLGQKAQTEVPKARINCPKSTTAYRSYCYYFSDYRETWSDA 60

Qy         61 DLYCQNMNSGNLVSVLTQAEGAFVASLIKESGTDDFNVWIGLHDPKKNRRWHWSSGSLVS 120
               ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db         61 YLYCQNMNSGNLVSVLTQAEGAFVASLIKESGTDDFNVWIGLHDPKKNRRWHWSSGSLVS 120

Qy        121 YKSWGIGAPSSVNPGYCVSLTSSTGFQKWKDVPCEDKFSFVCKFKN 166
               ||||||||||||||||||||||||||||||||||||||||||||||
Db        121 YKSWGIGAPSSVNPGYCVSLTSSTGFQKWKDVPCEDKFSFVCKFKN 166


RESULT 14
ADS98793
ID   ADS98793 standard; protein; 166 AA.
XX
AC   ADS98793;
XX
DT   30-DEC-2004  (first entry)
XX
DE   Protein factor discovery related human contig polypeptide, SEQ ID 1057.
XX
KW   antiinflammatory; cytostatic; antimicrobial; gene therapy; inflammation;
KW   leukaemia; nervous system disorder; infection.
XX
OS   Homo sapiens.
XX
PN   WO2004087874-A2.
XX
PD   14-OCT-2004.
XX
PF   24-MAR-2004; 2004WO-US009202.
XX
PR   28-MAR-2003; 2003US-0458824P.
XX
PA   (NUVE-) NUVELO INC.
PA   (DRMA/) DRMANAC R T.
XX
PI   Tang YT,  Zhou P,  Wang J,  Wang ZW,  Hu T;
XX
DR   WPI; 2004-737686/72.
DR   N-PSDB; ADS98453.
XX
PT   New polynucleotides encoding a polypeptide with biological activity,
PT   useful for treating inflammation, leukemias, nervous system disorders, or
PT   infections.
XX
PS   Example 3; SEQ ID NO 1057; 253pp; English.
XX
CC   The invention relates to a novel isolated polynucleotide comprising any
CC   of the 235 nucleotide sequences described in the specification. The
```

```
CC   invention further comprises: an isolated polynucleotide encoding a
CC   polypeptide with biological activity, where the polynucleotide hybridizes
CC   to one of the 235 novel polynucleotides under stringent hybridization
CC   conditions, or having greater than about 99% sequence identity with the
CC   novel polynucleotide; a vector comprising a novel polynucleotide; an
CC   expression vector comprising the novel polynucleotide; a host cell
CC   genetically engineered to comprise the novel polynucleotide, which can be
CC   operatively associated with a regulatory sequence that modulates
CC   expression of the polynucleotide in the host cell; an isolated
CC   polypeptide encoded by the novel polynucleotide, or a polynucleotide
CC   hybridizing under stringent conditions to the novel polynucleotide; a
CC   composition comprising the polypeptide and a carrier; an antibody
CC   directed against the polypeptide; a method for detecting the novel
CC   polynucleotide in a sample; a method for detecting the polypeptide in a
CC   sample; a method for identifying a compound that binds to the polypeptide
CC   ; a method for producing the polypeptide; an isolated polypeptide
CC   comprising any of the 235 amino acid sequences described in the
CC   specification; and a collection of polynucleotides comprising of at least
CC   one of the polynucleotides cited above. The polypeptides and
CC   polynucleotides of the invention have antiinflammatory, cytostatic, and
CC   antimicrobial activities. The novel polynucleotide may be used to treat
CC   disorders by gene therapy. The polypeptides and polynucleotides are
CC   useful for treating inflammation, leukaemias, nervous system disorders,
CC   or infections. This sequence represents the polypeptide encoded by
CC   contiguous DNA derived from one of the 235 novel isolated polynucleotides
CC   of the invention.
XX
SQ   Sequence 166 AA;

  Query Match             90.0%;  Score 817;  DB 8;  Length 166;
  Best Local Similarity   89.8%;  Pred. No. 1.7e-71;
  Matches  149;  Conservative    7;  Mismatches   10;  Indels    0;  Gaps    0;

Qy          1 MAQTSSYFMLISCLMFLSQSQGQEAQTELPQARISCPEGTNAYRSYCYYFNEDRETWVDA 60
              || | ||||| |||||| || ||:||||:|:|||:||: | ||||||||::: |||| ||
Db          1 MAHTRSYFMLNSCLMFLPQSLGQKAQTEVPKARINCPKSTTAYRSYCYYFSDYRETWSDA 60

Qy         61 DLYCQNMNSGNLVSVLTQAEGAFVASLIKESGTDDFNVWIGLHDPKKNRRWHWSSGSLVS 120
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db         61 YLYCQNMNSGNLVSVLTQAEGAFVASLIKESGTDDFNVWIGLHDPKKNRRWHWSSGSLVS 120

Qy        121 YKSWGIGAPSSVNPGYCVSLTSSTGFQKWKDVPCEDKFSFVCKFKN 166
              ||||||||||||||||||||||||||||||||||||||||||||||||
Db        121 YKSWGIGAPSSVNPGYCVSLTSSTGFQKWKDVPCEDKFSFVCKFKN 166


RESULT 15
AAR66591
ID   AAR66591 standard; protein; 146 AA.
XX
AC   AAR66591;
XX
DT   25-MAR-2003  (revised)
DT   03-FEB-1995  (first entry)
XX
DE   Human reg protein (Gln21-Asn166).
XX
KW   Human reg protein; blood sugar level depressant; hypoglycaemic agent;
KW   diabetes; hyperglycaemia; cell proliferation; islets of Langerhans.
XX
OS   Homo sapiens.
```



```
XX
PN   WO9412203-A1.
XX
PD   09-JUN-1994.
XX
PF   01-DEC-1993;   93WO-JP001746.
XX
PR   01-DEC-1992;   92JP-00322121.
PR   19-APR-1993;   93JP-00091576.
XX
PA   (SHIO ) SHIONOGI SEIYAKU KK.
XX
PI   Okamoto H;
XX
DR   WPI; 1994-199962/24.
XX
PT   Sugar level depressants and cell proliferation agents comprising reg
PT   proteins - for treatment of diabetes, and inducing growth of islets of
PT   Langerhans.
XX
PS   Claim 1; Page 11; 20pp; Japanese.
XX
CC   This is one of three specified subfragments of the human reg protein
CC   which are claimed for use as blood sugar level depressants to treat
CC   diabetes. They are also useful to induce proliferation of cells in the
CC   islets of Langerhans. (Updated on 25-MAR-2003 to correct PN field.)
XX
SQ   Sequence 146 AA;

  Query Match             89.2%;  Score 810;  DB 2;  Length 146;
  Best Local Similarity   100.0%;  Pred. No. 6.8e-71;
  Matches  146;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy         21 QGQEAQTELPQARISCPEGTNAYRSYCYYFNEDRETWVDADLYCQNMNSGNLVSVLTQAE 80
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db          1 QGQEAQTELPQARISCPEGTNAYRSYCYYFNEDRETWVDADLYCQNMNSGNLVSVLTQAE 60

Qy         81 GAFVASLIKESGTDDFNVWIGLHDPKKNRRWHWSSGSLVSYKSWGIGAPSSVNPGYCVSL 140
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db         61 GAFVASLIKESGTDDFNVWIGLHDPKKNRRWHWSSGSLVSYKSWGIGAPSSVNPGYCVSL 120

Qy        141 TSSTGFQKWKDVPCEDKFSFVCKFKN 166
              ||||||||||||||||||||||||||
Db        121 TSSTGFQKWKDVPCEDKFSFVCKFKN 146


Search completed: May 24, 2007, 16:30:09
Job time : 132.5 secs
```

SCORE 2.0 BuildDate: 12/05/2005